View Filing Data

Print Document View Excel Document

Cover Page - shares	9 Months Ended
Cover Page - shares	Sep. 30, 2019	Nov. 03, 2019
Cover page.
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2019
Document Transition Report	false
Entity File Number	001-35060
Entity Registrant Name	PACIRA BIOSCIENCES, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	51-0619477
Entity Address, Address Line One	5 Sylvan Way, Suite 300
Entity Address, City or Town	Parsippany
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07054
City Area Code	973
Local Phone Number	254-3560
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	PCRX
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		41,730,807
Entity Central Index Key	0001396814
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2019
Document Fiscal Period Focus (Q1,Q2,Q3,FY)	Q3
Amendment Flag	false

CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 85,139,000	$ 132,526,000
Short-term investments	180,505,000	250,928,000
Accounts receivable, net	42,573,000	38,000,000
Inventories, net	60,238,000	48,569,000
Prepaid expenses and other current assets	10,392,000	7,946,000
Total current assets	378,847,000	477,969,000
Long-term investments	70,577,000	25,871,000
Fixed assets, net	104,856,000	108,670,000
Right-of-use assets, net	35,756,000	0
Goodwill	99,547,000	62,040,000
Intangible assets, net	106,354,000	0
Equity investment and other assets	11,552,000	14,803,000
Total assets	807,489,000	689,353,000
Current liabilities:
Accounts payable	16,064,000	14,368,000
Accrued expenses	61,002,000	45,865,000
Lease liabilities	5,043,000	0
Convertible senior notes	0	338,000
Contingent consideration	13,591,000	0
Income taxes payable	138,000	90,000
Total current liabilities	95,838,000	60,661,000
Convertible senior notes	302,081,000	290,592,000
Lease liabilities	38,882,000	0
Contingent consideration	22,206,000	0
Other liabilities	2,320,000	16,874,000
Total liabilities	461,327,000	368,127,000
Commitments and contingencies (Note 16)
Stockholders’ equity:
Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued and outstanding at September 30, 2019 and December 31, 2018	0	0
Common stock, par value $0.001; 250,000,000 shares authorized; 41,700,320 shares issued and outstanding at September 30, 2019; 41,222,799 shares issued and outstanding at December 31, 2018	42,000	41,000
Additional paid-in capital	740,183,000	709,691,000
Accumulated deficit	(394,510,000)	(388,226,000)
Accumulated other comprehensive income (loss)	447,000	(280,000)
Total stockholders’ equity	346,162,000	321,226,000
Total liabilities and stockholders’ equity	$ 807,489,000	$ 689,353,000

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	41,700,320	41,222,799
Common stock, shares outstanding	41,700,320	41,222,799
Treasury stock at cost, shares	0	0

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Collaborative Licensing and Development Revenue	$ 0	$ 0	$ 0	$ 3,000,000
Revenues:
Total revenues	104,685,000	83,448,000	298,602,000	242,163,000
Operating expenses:
Cost of goods sold	22,304,000	19,065,000	74,809,000	62,866,000
Research and development	20,255,000	14,897,000	52,466,000	41,514,000
Selling, general and administrative	50,128,000	44,179,000	146,559,000	132,619,000
Amortization of acquired intangible assets	1,967,000	0	3,736,000	0
Acquisition-related charges and product discontinuation, net	7,618,000	1,259,000	12,266,000	1,511,000
Total operating expenses	102,272,000	79,400,000	289,836,000	238,510,000
Income from operations	2,413,000	4,048,000	8,766,000	3,653,000
Other (expense) income:
Interest income	1,736,000	1,586,000	5,709,000	4,493,000
Interest expense	(5,940,000)	(5,642,000)	(17,631,000)	(16,195,000)
Other, net	(4,025,000)	(694,000)	(4,051,000)	(699,000)
Total other expense, net	(8,229,000)	(4,750,000)	(15,973,000)	(12,401,000)
Income (loss) before income taxes	(5,816,000)	(702,000)	(7,207,000)	(8,748,000)
Income tax (expense) benefit	(271,000)	62,000	1,079,000	(8,000)
Net loss	$ (6,087,000)	$ (640,000)	$ (6,128,000)	$ (8,756,000)
Earnings Per Share, Basic and Diluted	$ (0.15)	$ (0.02)	$ (0.15)	$ (0.21)
Weighted average common shares outstanding:
Basic (in shares)	41,645	40,995	41,423	40,833
Product [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 104,350,000	$ 82,708,000	$ 297,080,000	$ 237,713,000
Royalty [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 335,000	$ 740,000	$ 1,522,000	$ 1,450,000

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Statement of Comprehensive Income [Abstract]
Net loss	$ (6,087)	$ (640)	$ (6,128)	$ (8,756)
Other comprehensive income (loss):
Net unrealized gain (loss) on investments	(53)	304	727	213
Total other comprehensive income (loss)	(53)	304	727	213
Comprehensive loss	$ (6,140)	$ (336)	$ (5,401)	$ (8,543)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Convertible Senior Notes Due 2019	Convertible Senior Notes Due 2019 Additional Paid-In Capital
Increase (Decrease) in Stockholders' Equity
Cumulative effect adjustment of the adoption of Accounting Standards Updates \| Accounting Standards Update 2018-07			$ (20)	$ 20
Balances (in shares) at Dec. 31, 2017		40,669,000
Balance at beginning of period at Dec. 31, 2017	$ 279,483	$ 41	669,032	(389,136)	$ (454)
Increase (Decrease) in Stockholders' Equity
Exercise of stock options (in shares)		207,000
Exercise of stock options	4,474	$ 0	4,474
Vested restricted stock units (in shares)		150,000
Vested restricted stock units	0	$ 0
Shares issued under employee stock purchase plan (shares)		35,000
Shares issued under employee stock purchase plan	952		952
Stock-based compensation	23,539		23,539
Net unrealized gain (loss) on investments	213				213
Net loss	(8,756)			(8,756)
Balances (in shares) at Sep. 30, 2018		41,061,000
Balance at end of period at Sep. 30, 2018	301,266	$ 41	697,977	(396,511)	(241)
Balances (in shares) at Jun. 30, 2018		40,955,000
Balance at beginning of period at Jun. 30, 2018	290,513	$ 41	686,888	(395,871)	(545)
Increase (Decrease) in Stockholders' Equity
Exercise of stock options (in shares)		104,000
Exercise of stock options	2,981		2,981
Vested restricted stock units (in shares)		2,000
Vested restricted stock units	0
Stock-based compensation	8,108		8,108
Net unrealized gain (loss) on investments	304				304
Net loss	(640)			(640)
Balances (in shares) at Sep. 30, 2018		41,061,000
Balance at end of period at Sep. 30, 2018	301,266	$ 41	697,977	(396,511)	(241)
Balances (in shares) at Dec. 31, 2018		41,223,000
Balance at beginning of period at Dec. 31, 2018	321,226	$ 41	709,691	(388,226)	(280)
Increase (Decrease) in Stockholders' Equity
Exercise of stock options (in shares)		251,000
Exercise of stock options	4,995	$ 1	4,994
Vested restricted stock units (in shares)		190,000
Vested restricted stock units	$ 0	$ 0
Shares issued under employee stock purchase plan (shares)	35,766	36,000
Shares issued under employee stock purchase plan	$ 1,270		1,270
Stock-based compensation	24,461		24,461
Retirement of equity component of 2019 convertible senior notes						$ (233)	$ (233)
Net unrealized gain (loss) on investments	727				727
Net loss	(6,128)			(6,128)
Balances (in shares) at Sep. 30, 2019		41,700,000
Balance at end of period at Sep. 30, 2019	346,162	$ 42	740,183	(394,510)	447
Balances (in shares) at Jun. 30, 2019		41,606,000
Balance at beginning of period at Jun. 30, 2019	341,650	$ 42	729,531	(388,423)	500
Increase (Decrease) in Stockholders' Equity
Exercise of stock options (in shares)		92,000
Exercise of stock options	1,408		1,408
Vested restricted stock units (in shares)		2,000
Vested restricted stock units	0	$ 0
Stock-based compensation	9,244		9,244
Net unrealized gain (loss) on investments	(53)				(53)
Net loss	(6,087)			(6,087)
Balances (in shares) at Sep. 30, 2019		41,700,000
Balance at end of period at Sep. 30, 2019	346,162	$ 42	$ 740,183	(394,510)	$ 447
Increase (Decrease) in Stockholders' Equity
Cumulative effect adjustment of the adoption of Accounting Standards Updates	(156)			(156)
Cumulative effect adjustment of the adoption of Accounting Standards Updates \| Accounting Standards Update 2014-09	$ 1,361			$ 1,361

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	Sep. 30, 2019	Sep. 30, 2018
Operating activities:
Net loss	$ (6,128,000)	$ (8,756,000)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation of fixed assets and amortization of intangible assets	14,486,000	9,114,000
Amortization of unfavorable lease obligation and debt issuance costs	1,273,000	1,186,000
Amortization of debt discount	10,216,000	9,512,000
Loss on disposal and impairment of fixed assets	998,000	10,000
Stock-based compensation	24,461,000	23,539,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	7,327,000	0
Loss on equity investment	(3,957,000)	(854,000)
Changes in operating assets and liabilities (net of MyoScience, Inc. acquisition):
Accounts receivable, net	(3,567,000)	(2,265,000)
Inventories, net	(9,967,000)	(3,473,000)
Prepaid expenses and other assets	(2,451,000)	(1,412,000)
Accounts payable	829,000	(1,400,000)
Accrued expenses and income taxes payable	4,004,000	(71,000)
Other liabilities	(822,000)	812,000
Net cash provided by operating activities	44,616,000	27,650,000
Investing activities:
Acquisition of MyoScience, Inc. (net of cash acquired)	(118,683,000)	0
Purchases of fixed assets	(5,662,000)	(12,271,000)
Purchases of investments	(220,091,000)	(182,750,000)
Sales of investments	248,365,000	345,602,000
Payment of contingent consideration	0	(6,842,000)
Equity Investment	(1,622,000)	0
Net cash (used in) provided by investing activities	(97,693,000)	143,739,000
Financing activities:
Proceeds from exercises of stock options	4,991,000	4,474,000
Proceeds from shares issued under employee stock purchase plan	1,270,000	952,000
Repayment of 2019 convertible senior notes	(338,000)	0
Conversion premium on convertible senior notes	(233,000)	0
Net cash provided by financing activities	5,690,000	5,426,000
Net (decrease) increase in cash and cash equivalents	(47,387,000)	176,815,000
Cash and cash equivalents, beginning of period	132,526,000	54,126,000
Cash and cash equivalents, end of period	85,139,000	230,941,000
Supplemental cash flow information:
Cash paid for interest	4,102,000	4,108,000
Income Taxes Paid, Net	702,000	146,000
Non-cash investing and financing activities:
Net increase in contingent consideration liabilities	28,470,000	0
Net increase (decrease) in accrued fixed assets	$ 1,663,000	$ (130,000)

DESCRIPTION OF BUSINESS	9 Months Ended
DESCRIPTION OF BUSINESS	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS	DESCRIPTION OF BUSINESS Pacira BioSciences, Inc. and its subsidiaries (collectively, the “Company” or “Pacira”) is a leading provider of non-opioid pain management options to advance and improve outcomes for health care practitioners and their patients. The Company’s long-acting, local analgesic, EXPAREL^®(bupivacaine liposome injectable suspension), was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam^®, a unique and proprietary delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, the Company added iovera°^®to its commercial offering with its acquisition of MyoScience, Inc., or MyoScience. The iovera° system is a handheld cryoanalgesia device used to deliver a precise, controlled application of cold temperature to only targeted nerves. The Company changed its name from Pacira Pharmaceuticals, Inc. to Pacira BioSciences, Inc. upon completing the acquisition of MyoScience in order to better reflect a broadening portfolio of innovative non-opioid pain management and regenerative health solutions. See Note 4, MyoScience Acquisition, for more information. Pacira is subject to risks common to companies in similar industries and stages, including, but not limited to, competition from larger companies, reliance on revenue from two products, reliance on a limited number of manufacturing sites, new technological innovations, dependence on key personnel, reliance on third-party service providers and sole source suppliers, protection of proprietary technology, compliance with government regulations and risks related to cybersecurity.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Principles of Consolidation

These interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules and regulations of the United States Securities and Exchange Commission, or SEC, for interim reporting. Pursuant to these rules and regulations, certain information and footnote disclosures normally included in complete annual financial statements have been condensed or omitted. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.

The condensed consolidated financial statements at September 30, 2019, and for the three and nine month periods ended September 30, 2019 and 2018, are unaudited, but include all adjustments (consisting of only normal recurring adjustments) which, in the opinion of management, are necessary to present fairly the financial information set forth herein in accordance with GAAP. The condensed consolidated balance sheet at December 31, 2018 is derived from the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. The condensed consolidated financial statements as presented reflect certain reclassifications from previously issued financial statements to conform to the current year presentation. The accounts of wholly-owned subsidiaries are included in the condensed consolidated financial statements. Intercompany accounts and transactions have been eliminated in consolidation.

The results of operations for these interim periods are not necessarily indicative of results that may be expected for any other interim periods or for the full year.

Concentration of Major Customers

The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers (including AmerisourceBergen Health Corporation, Cardinal Health, Inc. and McKesson Drug Company), but shipments of the product are sent directly to individual accounts, such as hospitals, ambulatory surgery centers and individual doctors. The Company also sells EXPAREL directly to ambulatory surgery centers and physicians. The Company sells its bupivacaine liposome injectable suspension for use in animals to a third party licensee and sells iovera° directly to end users. The table below includes the percentage of revenue comprised by the Company’s three largest wholesalers in each period presented:



	Three Months Ended September 30,		Nine Months Ended September 30,
	2019	2018	2019	2018
Largest wholesaler	34%	34%	34%	34%
Second largest wholesaler	29%	30%	29%	30%
Third largest wholesaler	27%	26%	26%	26%
Total	90%	90%	89%	90%

Recently Adopted Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2016-02, Leases (Topic 842), and subsequently issued clarifications and corrections to the update by issuing ASU 2018-10 in July 2018. This update required lessees to recognize lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous authoritative guidance. For income statement purposes, the new standard retained a dual model similar to Accounting Standards Codification, or ASC, 840, requiring leases to be classified as either operating or financing. Operating leases continue to result in straight-line expense while financing leases result in a front-loaded expense pattern (similar to previous accounting guidance by lessees for operating and capital leases, respectively, under ASC 840).

The Company adopted ASU 2016-02 on January 1, 2019 using the effective date method. There were practical expedients available to the Company at transition that it elected to apply upon adoption. The Company did not re-assess (i) whether its contracts contained a lease under the new definition of a lease and (ii) the classification of those leases. There were no initial direct costs previously capitalized on the consolidated balance sheet. In addition, the Company applied hindsight in the determination of the lease terms, in the assessment of the likelihood that a lease renewal, termination or purchase option will be exercised, and in the assessment of any potential impairments that existed on the right-of-use, or ROU, assets recognized at adoption. The Company also elected not to recognize a ROU asset and lease liability for those leases with a remaining lease term of 12 months or less.

At adoption on January 1, 2019, the lease liability was equal to the present value of future lease payments and a ROU asset was recorded based on the lease liability, adjusted for items such as prepaid and accrued lease payments. The Company recorded $36.5 million of lease liabilities and $27.6 million of ROU assets as of January 1, 2019, the difference representing previously recorded lease-related assets and liabilities. There was a cumulative-effect adjustment to retained earnings of $0.2 million upon adoption. Refer to Note 7, Leases, for further information on the Company’s existing leases.

The lease liability recognized upon adoption was based upon the present value of the sum of the remaining minimum lease payments (as previously identified under ASC 840), determined using the discount rate as of the date of adoption. The discount rate was based on the Company’s incremental borrowing rate on a collateralized basis over a similar remaining term and in a similar economic environment.

Recent Accounting Pronouncements Not Adopted as of September 30, 2019

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. Entities will now use forward-looking information to better form their credit loss estimates. This update also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an entity’s portfolio. This standard will become effective for the Company beginning January 1, 2020, with early adoption permitted. The Company does not expect there to be a significant impact from the adoption of ASU 2016-13 on its consolidated financial statements.

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework. The purpose of the update is to improve the effectiveness of the fair value measurement disclosures that allows for clear communication of information that is most important to the users of financial statements. There were certain required disclosures that have been removed or modified. In addition, the update added the following disclosures: (i) changes in unrealized gains and losses for the period included in other comprehensive income (loss) for recurring Level 3 fair value measurements held at the end of the reporting period and (ii) the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. The standard will become effective for the Company beginning January 1, 2020. The Company does not expect there to be a significant impact from the adoption of ASU 2018-13 on its consolidated financial statements.

In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract, which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The update provides guidance to determine which implementation costs to capitalize as they relate to the service contract and which costs to expense. In addition, the update further defines the term of the hosting arrangement to include the non-cancelable period of the arrangement plus periods covered by (i) an option to extend the arrangement if the customer is reasonably certain to exercise that option; (ii) an option to terminate the arrangement if the customer is reasonably certain not to exercise the termination option and (iii) an option to extend (or not to terminate) the arrangement in which exercise of the option is in the control of the vendor. Any expense related to the capitalized implementation costs should be recorded in the same financial statement line item in the consolidated statements of operations as the fees associated with the hosting element of the arrangement, and the payments for capitalized implementation costs should be classified in the same manner as payments made for fees associated with the hosting element in the consolidated statements of cash flows. This standard will become effective for the Company beginning January 1, 2020. The amendments may be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The Company expects to apply ASU 2018-15 on a prospective basis. The Company will apply this standard to future implementation costs incurred. The impact of ASU 2018-15 will be dependent upon future projects entered into by the Company subsequent to the date of adoption.

In April 2019, the FASB issued ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, which provides amendments to the recognition and measurement of certain financial assets and financial liabilities. One of those amendments requires that equity securities without readily determinable fair values accounted for under the measurement alternative be re-measured when an orderly transaction is identified for an identical or similar investment of the same issuer. This standard will become effective for the Company beginning January 1, 2020. The Company does not expect there to be a significant impact from the adoption of ASU 2019-04 on its consolidated financial statements.

Other pronouncements issued by the FASB or other authoritative accounting standards groups with future effective dates are either not applicable or not significant to the consolidated financial statements of the Company.

Significant Accounting Policies

Leases

Effective January 1, 2019, the Company recognizes ROU assets and lease liabilities at the commencement of its lease agreements. The leases are evaluated at commencement to determine whether they should be classified as operating or financing leases. Lease costs associated with operating leases are recognized on a straight-line basis, while lease costs for financing leases are recognized over the lease term using the effective interest method. To date, the Company does not have any financing leases. The amount of ROU assets and lease liabilities to be recognized is impacted by the type of lease payments, the lease term and the incremental borrowing rate. Variable lease payments are not included at commencement and are recognized in the period in which they are incurred. The lease term is based on the contractual term and is adjusted for any renewal options or termination rights that are reasonably certain to be exercised. The incremental borrowing rate is based on the rate the Company estimates it would pay on a collateralized basis over a similar term in a similar economic environment.

Acquisitions

In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with some exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company’s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company’s condensed consolidated financial statements after the date of the acquisition. If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than as a business combination and, therefore, no goodwill would be recorded.

Contingent Consideration

Subsequent to an acquisition, the Company measures contingent consideration arrangements at fair value for each period with changes in fair value recognized in the consolidated statements of operations as acquisition-related charges. Changes in contingent consideration can result from changes in the assumed achievement and timing of estimated sales, costs of goods sold and regulatory approvals. In the absence of new information, changes in fair value reflect the passage of time towards achievement of the milestones, and are accrued based on an accretion schedule.

Intangible Assets

Intangible assets with definite useful lives are amortized on a straight-line basis over their estimated useful lives and are reviewed for impairment if certain events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Intangible assets are recorded at cost, net of accumulated amortization. The Company evaluates the recoverability of intangible assets periodically and takes into account events and circumstances which may indicate that an impairment exists.

Segment Reporting

The Company is managed and operated as a single business focused on the discovery, development, manufacture, marketing, distribution and sale of non-opioid pain management options. The Company is managed by a single management team, and, consistent with its organizational structure, the Chief Executive Officer and Chairman manages and allocates resources at a consolidated level. Accordingly, the Company views its business as one reportable operating segment to evaluate performance, allocate resources, set operational targets and forecast its future period financial results.

REVENUE

9 Months Ended

Sep. 30, 2019

Revenue from Contract with Customer [Abstract]

REVENUE

Revenue from Contracts with Customers

The Company’s sources of revenue include (i) sales of EXPAREL/bupivacaine liposome injectable suspension in the United States, or U.S.; (ii) sales of iovera° in the U.S.; (iii) royalties based on sales of its bupivacaine liposome injectable suspension product for use in animals and (iv) license fees and milestone payments. The majority of the Company’s revenue is derived from net product sales of EXPAREL. As such, the following disclosure only relates to revenue associated with net EXPAREL product sales.

Net Product Sales

The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers based on orders of the product placed by end-users which include hospitals, ambulatory surgery centers and doctors. EXPAREL is delivered directly to the end-user without the wholesaler ever taking physical possession of the product. Product revenue is recognized when control of the promised goods are transferred to the customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for transferring those goods. EXPAREL revenue is recorded at the time the product is delivered to the end-user.

Revenues from sales of products are recorded net of returns allowances, prompt payment discounts, wholesaler service fees, volume rebates and chargebacks. These reserves are based on estimates of the amounts earned or to be claimed on the related sales. These amounts are treated as variable consideration, estimated and recognized as a reduction of the transaction price at the time of the sale, using the most likely amount method for the gross to net adjustments, except for returns, which is based on the expected value method. The Company includes these estimated amounts in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized for such transaction will not occur, or when the uncertainty associated with the variable consideration is resolved. The calculation of some of these items requires management to make estimates based on sales data, historical return data, contracts and other related information that may become known in the future. The adequacy of these provisions is reviewed on a quarterly basis.

Accounts Receivable

The majority of accounts receivable arise from product sales and represent amounts due from wholesalers, hospitals, ambulatory surgery centers and doctors. Payment terms generally range from zero to 37 days from the date of the transaction, and accordingly, there is no significant financing component.

Performance Obligations

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.

At contract inception, the Company assesses the goods promised in its contracts with customers and identifies a performance obligation for each promise to transfer to the customer a good that is distinct. When identifying individual performance obligations, the Company considers all goods promised in the contract regardless of whether explicitly stated in the customer contract or implied by customary business practices. The Company’s contracts with customers require it to transfer an individual distinct product, which represents a single performance obligation. The Company’s performance obligation with respect to its product sales is satisfied at a point in time, which transfers control upon delivery of EXPAREL to its customers. The Company considers control to have transferred upon delivery because the customer has legal title to the asset, physical possession of the asset has been transferred, the customer has significant risks and rewards of ownership of the asset and the Company has a present right to payment at that time.

Disaggregated Revenue

The following table represents disaggregated net product sales in the periods presented as follows (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
Net Product Sales	2019		2018		2019		2018
EXPAREL / bupivacaine liposome injectable suspension	$	101,711	$	82,708	$	292,406	$	237,713
iovera°	2,639		—		4,674		—
Total net product sales	$	104,350	$	82,708	$	297,080	$	237,713

MYOSCIENCE ACQUISITION

9 Months Ended

Sep. 30, 2019

Business Combinations [Abstract]

MYOSCIENCE ACQUISITION

On April 9, 2019, the Company acquired MyoScience (the “MyoScience Acquisition”), a privately-held medical device company, pursuant to the terms of an Agreement and Plan of Merger (the “Merger Agreement”), under which MyoScience became a wholly-owned subsidiary of the Company and was renamed Pacira CryoTech, Inc., or CryoTech. The MyoScience Acquisition added iovera° to the Company’s commercial offering. The iovera° system is a novel, United States Food and Drug Administration, or FDA, approved, non-opioid treatment that immediately alleviates pain for up to 90 days by applying intense cold to only targeted nerves in a process called cryoanalgesia.

The consideration included an initial cash payment of $120.0 million, reduced by $1.0 million for post-closing purchase price adjustments and indemnification obligations incurred to date, and the fair value of contingent consideration in the amount of $28.5 million. The contingent consideration consists of contingent milestone payments up to an aggregate of $100.0 million upon the achievement of certain regulatory and commercial milestones, of which up to $25.0 million may be payable in shares of the Company’s common stock if achieved in 2020. Per the terms of the Merger Agreement, the Company’s obligation to make milestone payments is limited to those milestones achieved between January 1, 2019 and December 31, 2023, and are to be paid within 60 days of the end of the fiscal quarter of achievement. In the third quarter of 2019, the Company met a regulatory milestone which was previously accrued and will result in a $7.0 million payment to be made in the fourth quarter of 2019. The Company also expects to meet another regulatory milestone which was previously accrued that would result in a $5.0 million payment to be made in 2020. For more information regarding contingent milestone payments subsequent to September 30, 2019, refer to Note 17, Subsequent Events.

The Company has accounted for the MyoScience Acquisition using the acquisition method of accounting and, accordingly, has included the assets acquired, liabilities assumed and results of operations in the condensed consolidated financial statements from April 10, 2019 onward, the day following the acquisition date. The excess of the purchase price over the fair value of identifiable net assets acquired represents goodwill. This goodwill is primarily attributable to the value of combining iovera° and EXPAREL as a safe and effective non-opioid multimodal regimen for pain management, as well as the synergies of merging operations. The primary assets and liabilities of the business acquired include developed technology and customer relationship intangible assets, equipment, inventory, receivables, payables and accrued expenses. Inventory has been recorded at its estimated selling price less costs of distribution and a reasonable profit, and the intangible assets acquired (including developed technology and customer relationships) have been recorded at fair value as determined by the Company’s management with the assistance of a third-party valuation specialist. The acquired goodwill and intangible assets are currently

not deductible for tax purposes. However, the Company is considering certain tax elections that would allow for the future deduction of acquired goodwill and intangible assets. See Note 8, Goodwill and Intangible Assets, for more information.

The total consideration for the MyoScience Acquisition was $147.5 million, which consisted of the following (in thousands):



Purchase Price	Amount
Cash paid, adjusted for working capital items	$	119,038
Fair value of contingent consideration	28,470
Total	$	147,508

The preliminary purchase price allocation is based on estimates, assumptions, valuations and other studies which have not yet been finalized. Prior to the finalization of the purchase price allocation, if information becomes available that would indicate it is probable that unknown events had occurred and the amounts can be reasonably estimated, such items will be included in the final purchase price allocation and may change the carrying value of goodwill. The Company is finalizing its valuation of the intangible assets and tax analyses, and anticipates finalizing the purchase price allocation as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date. The following tables set forth the preliminary allocation of the MyoScience Acquisition purchase price to the estimated fair value of the net assets acquired at the acquisition date (in thousands):



	Amounts Recognized at the Acquisition Date (Unaudited)
ASSETS ACQUIRED
Current assets	$	5,275
Non-current assets (other than intangible assets)	1,044
Intangible assets (excluding goodwill)	110,090
Total assets acquired (excluding goodwill)	$	116,409

LIABILITIES ASSUMED
Current liabilities	$	4,436
Deferred tax liabilities, net	1,828
Other non-current liabilities	144
Total liabilities assumed	6,408
Total identifiable net assets acquired	110,001
Goodwill	37,507
Total consideration transferred	$	147,508

CryoTech results from the acquisition date of April 10, 2019 through September 30, 2019, which are included in the condensed consolidated statements of operations, are as follows (in thousands):



Classification in Condensed Consolidated Statements of Operations	Acquisition Date Through September 30, 2019
Total revenues	$	4,674
Net loss	$	(5,555	)

Unaudited Pro Forma Summary of Operations

The following table shows the unaudited pro forma summary of operations for the three months ended September 30, 2018 and the nine months ended September 30, 2019 and 2018, as if the MyoScience Acquisition had occurred on January 1, 2018. This pro forma information does not purport to represent what the Company’s actual results would have been if the acquisition had occurred as of January 1, 2018, and is not indicative of what such results would be expected for any future period (in thousands, except per share amounts):



	Three Months Ended September 30,			Nine Months Ended September 30,
	2018			2019			2018
Total revenues	$	84,916		$	301,051		$	245,721
Net loss	$	(6,944	)	$	(10,633	)	$	(27,663	)
Pro forma basic and diluted net loss per share	$	(0.17	)	$	(0.26	)	$	(0.68	)

The unaudited pro forma financial information was prepared using the acquisition method of accounting and was based on the historical financial information of the Company and MyoScience. The summary pro forma financial information primarily reflects the following pro forma adjustments:


•	Removal of the acquisition-related transaction fees and costs, including certain stock-based compensation and other compensation expenses related to the acquisition, from the nine months ended September 30, 2019;


•	Removal of the income tax benefit resulting from the Company decreasing its existing valuation allowance on deferred tax assets from the nine months ended September 30, 2019;


•	Removal of MyoScience’s loss on extinguishment of debt and warrant expense in the nine months ended September 30, 2019;


•	Removal of MyoScience’s interest expense;


•	Adjustments to the Company’s interest income for the cash used to acquire MyoScience; and

•

The addition of amortization expense on the acquired developed technology and customer relationship intangible assets.

INVENTORIES

9 Months Ended

Sep. 30, 2019

Inventory Disclosure [Abstract]

INVENTORIES

The components of inventories, net are as follows (in thousands):



	September 30,		December 31,
	2019		2018
Raw materials	$	18,798	$	19,193
Work-in-process	17,472		9,711
Finished goods	23,968		19,665
Total	$	60,238	$	48,569

The Company is required to perform stability testing on select lots of EXPAREL. In October 2019, a single validation lot of EXPAREL manufactured at the Company’s contract manufacturing site located in the United Kingdom did not meet its required stability specification. The Company has temporarily halted production on the line while it investigates the root cause of the failure. Inventory from this line totals approximately $10.5 million. Depending on the outcome of the investigation and discussions with the FDA, it may be determined that some or all of this inventory may be unsellable. At this stage, no determination of an amount is possible.

FIXED ASSETS

9 Months Ended

Sep. 30, 2019

Property, Plant and Equipment [Abstract]

FIXED ASSETS

Fixed assets, net, summarized by major category, consist of the following (in thousands):



	September 30,			December 31,
	2019			2018
Machinery and equipment	$	68,342		$	67,431
Leasehold improvements	60,355			57,955
Computer equipment and software	8,381			8,131
Office furniture and equipment	1,625			1,548
Construction in progress	38,421			35,163
Total	177,124			170,228
Less: accumulated depreciation	(72,268		)	(61,558		)
Fixed assets, net	$	104,856		$	108,670

For the three months ended September 30, 2019 and 2018, depreciation expense was $3.6 million and $3.5 million, respectively, and for the three months ended both September 30, 2019 and 2018, there was less than $0.1 million of capitalized interest on the construction of manufacturing sites.

For the nine months ended September 30, 2019 and 2018, depreciation expense was $10.7 million and $9.1 million, respectively. For the nine months ended September 30, 2019 there was less than $0.1 million of capitalized interest on the construction of manufacturing sites, and for the nine months ended September 30, 2018, capitalized interest was $0.7 million.

At September 30, 2019 and December 31, 2018, total fixed assets, net, includes leasehold improvements and manufacturing process equipment located in Europe in the amount of $65.1 million and $64.6 million, respectively.

During the nine months ended September 30, 2019, the Company recorded increases to its asset retirement obligations, or AROs, of $0.3 million due to a revision in estimated future cash flows related to the AROs (including those resulting from the MyoScience Acquisition). Accretion expense was $0.1 million and $0.2 million in the three and nine months ended September 30, 2019, respectively.

LEASES

9 Months Ended

Sep. 30, 2019

Leases [Abstract]

LEASES

The Company leases its EXPAREL manufacturing, research and development, warehouse and former DepoCyt(e) manufacturing facilities in San Diego, California, its iovera° manufacturing, research and development and warehouse facility in Fremont, California and its corporate headquarters in Parsippany, New Jersey. These leases have remaining terms between one year and eleven years, some of which provide renewal options at the then-current market value, along with one that contains the right to terminate the lease after four years. The Company also has a lease with Thermo Fisher Scientific Pharma Services (“Thermo Fisher”) (formerly Patheon UK Limited), for the use of their facility in Swindon, England, which is embedded in agreements the Company has with Thermo Fisher. A portion of the associated monthly base fees has been allocated to the lease component based on a relative fair value basis.

The Company’s facility in Fremont, California, is dedicated to the iovera° product line and consists of approximately 20,000 square feet of mixed use manufacturing, research and development and office space. For a description of the Company’s other material properties, refer to its Annual Report on Form 10-K for the year ended December 31, 2018.

The operating lease costs for the facilities include lease and non-lease components, such as common area maintenance and other common operating expenses, along with executory costs such as insurance and real estate taxes. Total operating lease costs are as follows (in thousands):



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
Operating Lease Costs	2019		2018		2019		2018
Fixed lease costs	$	1,585	$	2,659	4,544		5,750
Variable lease costs	403		495		1,233		1,305
Total	$	1,988	$	3,154	$	5,777	$	7,055

Supplemental cash flow information related to operating leases is as follows (in thousands):



	Nine Months Ended
	September 30, 2019
Cash paid for operating lease liabilities, net of lease incentive	$	5,247
Right-of-use assets recorded in exchange for lease obligations	$	38,419

The Company has elected to net the amortization of the ROU asset and the reduction of the lease liability principal in accrued expenses in the condensed consolidated statement of cash flows.

The Company has measured its operating lease liabilities at an estimated discount rate in which it could borrow on a collateralized basis over the remaining term for each operating lease. The weighted average remaining lease term and the weighted average discount rate are summarized as follows:



		September 30, 2019
Weighted average remaining lease term		9.66 years
Weighted average discount rate		7.62%

Maturities of the Company’s operating lease liabilities are as follows (in thousands):



Year	Aggregate Minimum Payments Due
2019 (remaining three months)	$	2,039
2020	7,662
2021	5,359
2022	5,486
2023	5,616
2024 through 2030	37,208
Total lease payments	63,370

Less: imputed interest	(19,445		)
Total operating lease liabilities	$	43,925

The Company has entered into three lease agreements (not included in the table above) for which there are future obligations but the leases have not yet commenced as of September 30, 2019 (in thousands):



Year	Aggregate Minimum Payments Due
2019 (remaining three months)	$	27
2020	2,607
2021	4,878
2022	4,937
2023	5,081
2024 through 2030	35,848
Total future lease payments	$	53,378

As of December 31, 2018, aggregate annual minimum payments due under the Company’s lease obligations were as follows (in thousands):



Year	Aggregate Minimum Payments Due
2019	$	8,140
2020	7,621
2021	5,295
2022	5,417
2023	5,543
2024 through 2030	14,329
Total	$	46,345

GOODWILL AND INTANGIBLE ASSETS

9 Months Ended

Sep. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

GOODWILL AND INTANGIBLE ASSETS

Goodwill

Skyepharma Acquisition

In March 2007, the Company acquired from SkyePharma Holding, Inc. (now a subsidiary of Vectura Group plc), or Skyepharma, its California operating subsidiary named Pacira Pharmaceuticals, Inc. (the “Skyepharma Acquisition”). The Company’s goodwill arose in April 2012 from a contingent milestone payment to Skyepharma in connection with the Skyepharma Acquisition. The Skyepharma Acquisition was accounted for under Statement of Financial Accounting Standards 141, Accounting for Business Combinations, which was the effective GAAP standard at the Skyepharma Acquisition date. In connection with the Skyepharma Acquisition, the Company agreed to milestone payments for DepoBupivacaine products, including EXPAREL, as follows:


(i)	$10.0 million upon the first commercial sale in the United States (met April 2012);


(ii)	$4.0 million upon the first commercial sale in a major E.U. country (United Kingdom, France, Germany, Italy and Spain);


(iii)	$8.0 million when annual net sales collected reach $100.0 million (met September 2014);


(iv)	$8.0 million when annual net sales collected reach $250.0 million (met June 2016); and


(v)	$32.0 million when annual net sales collected reach $500.0 million.

For purposes of meeting future potential milestone payments, annual net sales are measured on a rolling quarterly basis.

As part of the Skyepharma Acquisition, the Company agreed to pay certain earn-out payments based on a percentage of net sales of DepoBupivacaine products collected, including EXPAREL, for the term during which such sales were covered by a valid claim in certain patent rights related to EXPAREL and other biologics products. The last patents for which a valid claim existed expired on September 18, 2018 and thus, the only remaining obligations to Skyepharma are the two unmet milestone payments totaling $36.0 million. Any remaining milestone payments will be treated as additional costs of the Skyepharma Acquisition and, therefore, recorded as goodwill if and when each contingency is resolved.

There was no change in the carrying value of goodwill related to the Skyepharma Acquisition during the three and nine months ended September 30, 2019.

MyoScience Acquisition

In connection with the MyoScience Acquisition, the Company recorded goodwill totaling $37.5 million. The acquired goodwill is currently not deductible for tax purposes. However, the Company is considering certain tax elections that would allow for the future deduction of this acquired goodwill. See Note 4, MyoScience Acquisition, for more information.

The change in the carrying value of the Company’s goodwill is summarized as follows (in thousands):



	Carrying Value of Goodwill
Balance at December 31, 2018	$	62,040
Goodwill arising from the MyoScience Acquisition	37,507
Balance at September 30, 2019	$	99,547

Intangible Assets

MyoScience Acquisition

Intangible assets, net, consist of the developed technology and customer relationships that were acquired in the MyoScience Acquisition and are summarized as follows (in thousands):



September 30, 2019	Gross Carrying Value		Accumulated Amortization			Intangible Assets, Net		Estimated Useful Life
Developed technology	$	110,000	$	(3,732	)	$	106,268	14 Years
Customer relationships	90		(4		)	86		10 Years
Total intangible assets	$	110,090	$	(3,736	)	$	106,354

There were no intangible assets, net, at December 31, 2018. Amortization expense on intangible assets for the three and nine months ended September 30, 2019 was $2.0 million and $3.7 million, respectively. There was no amortization expense on intangible assets for the three and nine months ended September 30, 2018.

For the remaining three months of 2019, amortization expense on intangible assets will be $2.0 million. Assuming no changes in the gross carrying amount of these intangible assets, the future amortization expense on intangible assets will be $7.9 million annually through 2032 and $2.2 million in 2033. These acquired intangible assets are currently not deductible for tax purposes. However, the Company is considering certain tax elections that would allow for the future deduction of these acquired intangible assets.

DEBT

9 Months Ended

Sep. 30, 2019

Debt Disclosure [Abstract]

DEBT

Convertible Senior Notes Due 2022

On March 13, 2017, the Company completed a private placement of $345.0 million in aggregate principal amount of 2.375% convertible senior notes due 2022, or 2022 Notes, and entered into an indenture, or 2022 Indenture, with respect to the 2022 Notes. The 2022 Notes accrue interest at a fixed rate of 2.375% per year, payable semiannually in arrears on April 1^st and October 1^st of each year. The 2022 Notes mature on April 1, 2022.

The total debt composition of the 2022 Notes is as follows (in thousands):



	September 30,			December 31,
	2019			2018
2.375% convertible senior notes due 2022	$	345,000		$	345,000
Deferred financing costs	(4,577		)	(5,850		)
Discount on debt	(38,342		)	(48,558		)
Total debt, net of debt discount and deferred financing costs	$	302,081		$	290,592

Holders may convert their 2022 Notes prior to October 1, 2021 only if certain circumstances are met, including if during the previous calendar quarter, the last reported sales price of the Company’s common stock was greater than 130% of the conversion price then applicable for at least 20 out of the last 30 consecutive trading days of the quarter. During the quarter ended September 30, 2019, this condition for conversion was not met.

On or after October 1, 2021, until the close of business on the second scheduled trading day immediately preceding April 1, 2022, holders may convert their 2022 Notes at any time.

Upon conversion, holders will receive the principal amount of their 2022 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the 40 consecutive trading days during the observation period (as more fully described in the 2022 Indenture). For both the principal and excess conversion value, holders may receive cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock, at the Company’s option. The initial conversion rate for the 2022 Notes is 14.9491 shares of common stock per $1,000 principal amount, which is equivalent to an initial conversion price of $66.89 per share of the Company’s common stock. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2022 Notes represents a premium of approximately 37.5% to the closing sale price of $48.65 per

share of the Company’s common stock on the Nasdaq Global Select Market on March 7, 2017, the date that the Company priced the private offering of the 2022 Notes.

As of September 30, 2019, the 2022 Notes had a market price of $987 per $1,000 principal amount. In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2022 Notes will be paid pursuant to the terms of the 2022 Indenture. In the event that all of the 2022 Notes are converted, the Company would be required to repay the $345.0 million in principal value and any conversion premium in any combination of cash and shares of its common stock (at the Company’s option).

Prior to April 1, 2020, the Company may not redeem the 2022 Notes. On or after April 1, 2020, the Company may redeem for cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock, at the Company’s option, all or part of the 2022 Notes if the last reported sale price (as defined in the 2022 Indenture) of the Company’s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading-day period ending within five trading days prior to the date on which the Company provides notice of redemption. The redemption price will equal the sum of (i) 100% of the principal amount of the 2022 Notes being redeemed, plus (ii) accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date. In addition, calling the 2022 Notes for redemption will constitute a “make whole fundamental change” (as defined in the 2022 Indenture) and will, in certain circumstances, increase the conversion rate applicable to the conversion of such notes if it is converted in connection with the redemption. No sinking fund is provided for the 2022 Notes.

While the 2022 Notes are currently classified on the Company’s consolidated balance sheet at September 30, 2019 as long-term debt, the future convertibility and resulting balance sheet classification of this liability will be monitored at each quarterly reporting date and will be analyzed dependent upon market prices of the Company’s common stock during the prescribed measurement periods. In the event that the holders of the 2022 Notes have the right to convert the 2022 Notes at any time during the prescribed measurement period, the 2022 Notes would then be considered a current obligation and classified as such.

Convertible Senior Notes Due 2019

On February 1, 2019, the Company’s 3.25% convertible senior notes due 2019, or 2019 Notes, matured, and the Company paid the remaining $0.3 million of principal in full, plus a $0.2 million conversion premium in cash. The 2019 Notes accrued interest at a fixed rate of 3.25% per year and were payable semiannually in arrears on February 1^st and August 1^st of each year.

Interest Expense

The following table sets forth the total interest expense recognized in the periods presented (dollar amounts in thousands):



	Three Months Ended September 30,						Nine Months Ended September 30,
	2019			2018			2019			2018
Contractual interest expense	$	2,048		$	2,051		$	6,146		$	6,153
Amortization of debt issuance costs	429			411			1,273			1,219
Amortization of debt discount	3,467			3,228			10,216			9,512
Capitalized interest (Note 6)	(4		)	(48		)	(4		)	(689		)
Total	$	5,940		$	5,642		$	17,631		$	16,195

Effective interest rate on convertible senior notes	7.81		%	7.81		%	7.81		%	7.81		%

FINANCIAL INSTRUMENTS

9 Months Ended

Sep. 30, 2019

Fair Value Disclosures [Abstract]

FINANCIAL INSTRUMENTS

Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in the principal or most advantageous market in an orderly transaction. To increase consistency and comparability in fair value measurements, the FASB established a three-level hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of fair value measurements are:


•	Level 1—Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.


•	Level 2—Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.


•	Level 3—Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

The carrying value of financial instruments including cash and cash equivalents, accounts receivable and accounts payable approximate their respective fair values due to the short-term nature of these items. The fair value of the Company’s convertible senior notes at September 30, 2019 are calculated utilizing market quotations from an over-the-counter trading market for these notes (Level 2). The fair value of the Company’s acquisition-related contingent consideration is reported at fair value on a recurring basis (Level 3). The carrying amount and fair values of the Company’s convertible senior notes and acquisition-related contingent consideration are as follows (in thousands):



Financial Liabilities	Carrying Value		Fair Value Measurements Using
September 30, 2019	Carrying Value		Level 1		Level 2		Level 3
2.375% convertible senior notes due 2022 ⁽¹⁾⁽²⁾	$	302,081	$	—	$	340,472	$	—
Acquisition-related contingent consideration ⁽³⁾	$	35,797	$	—	$	—	$	35,797

(1) The closing price of the Company’s common stock was $38.07 per share at September 30, 2019 compared to a conversion price of $66.89 per share. Currently, the conversion price is above the stock price. The maximum conversion premium that can be due on the 2022 Notes is approximately 5.2 million shares of the Company’s common stock, which assumes no increases in the conversion rate for certain corporate events.

(2) Reported at historical cost.

(3) Reported at fair value on a recurring basis.

Financial Liabilities Measured at Fair Value on a Recurring Basis

The Company has recognized contingent consideration in the amount of $35.8 million as of September 30, 2019. The contingent consideration was recognized as part of the MyoScience Acquisition in April 2019. Refer to Note 4, MyoScience Acquisition, for more information.

The Company’s contingent consideration obligations are recorded at their estimated fair values and are revalued each reporting period until the related contingencies are resolved. For the three and nine months ended September 30, 2019, the Company recognized $7.3 million of fair value adjustments related to contingent consideration, which have been included in acquisition-related charges in the condensed consolidated statements of operations. The Company has measured the fair value of its contingent consideration using a probability-weighted discounted cash flow approach that is based on unobservable inputs and a Monte Carlo simulation. These inputs include, as applicable, estimated probabilities and the timing of achieving specified commercial and regulatory milestones; estimated forecasts of revenue and costs and the discount rate used to calculate the present value of estimated future payments. Significant changes may increase or decrease the probabilities of achieving the related commercial and regulatory events, shorten or lengthen the time required to achieve such events, or increase or decrease estimated forecasts.

The following table includes the key assumptions used in the valuation of the Company’s contingent consideration:



Assumption		Ranges Utilized as of September 30, 2019
Discount rates		5.29% to 5.64%
Probabilities of payment for regulatory milestones		0% to 100% ⁽¹⁾
Projected years of payment for regulatory milestones		2019 to 2023
Projected years of payment for commercial milestones		Up to 4.25 years

(1) One of the regulatory milestones was met during the three months ended September 30, 2019, requiring a payment in the amount of $7.0 million to be made in the fourth quarter of 2019.

The maximum remaining potential payments related to the contingent consideration from the MyoScience Acquisition are $80.0 million.

The change in the Company’s contingent consideration recorded at fair value using Level 3 measurements is as follows (in thousands):



	Fair Value
Balance at December 31, 2018	$	—
New financial liabilities entered into on date of MyoScience Acquisition (April 9, 2019)	28,470
Fair value adjustments and accretion	7,327
Balance at September 30, 2019	$	35,797

Investments

Short-term investments consist of asset-backed securities collateralized by credit card receivables, investment grade commercial paper and corporate bonds with maturities greater than three months, but less than one year. Long-term investments consist of asset-backed securities collateralized by credit card receivables and corporate bonds with maturities greater than one year. Net unrealized gains and losses from the Company’s short-term and long-term investments are reported in other comprehensive income (loss). At September 30, 2019, all of the Company’s short-term investments are classified as available for sale investments and are determined to be Level 2 instruments, which are measured at fair value using standard industry models with observable inputs. The fair value of the commercial paper is measured based on a standard industry model that uses the three-month U.S. Treasury bill rate as an observable input. The fair value of the asset-backed securities and corporate bonds is principally measured or corroborated by trade data for identical issues in which related trading activity is not sufficiently frequent to be considered a Level 1 input or that of comparable securities. At September 30, 2019, all short-term and long-term investments had an “A” or better rating by Standard & Poor’s.

The following summarizes the Company’s investments at September 30, 2019 and December 31, 2018 (in thousands):



September 30, 2019 Investments	Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value (Level 2)
Short-term:
Asset-backed securities	$	29,044	$	60	$	—		$	29,104
Commercial paper	34,788		41		—			34,829
Corporate bonds	116,273		299		—			116,572
Subtotal	180,105		400		—			180,505
Long-term:
Asset-backed securities	16,518		23		(7		)	16,534
Corporate bonds	54,012		48		(17		)	54,043
Subtotal	70,530		71		(24		)	70,577
Total	$	250,635	$	471	$	(24	)	$	251,082



December 31, 2018 Investments	Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value (Level 2)
Short-term:
Asset-backed securities	$	34,873	$	—	$	(33	)	$	34,840
Commercial paper	45,035		—		(30		)	45,005
Corporate bonds	171,289		—		(206		)	171,083
Subtotal	251,197		—		(269		)	250,928
Long-term:
Asset-backed securities	9,383		5		—			9,388
Corporate bonds	16,499		—		(16		)	16,483
Subtotal	25,882		5		(16		)	25,871
Total	$	277,079	$	5	$	(285	)	$	276,799

Certain assets and liabilities are measured at fair value on a nonrecurring basis, including assets and liabilities acquired in a business combination, any related contingent consideration arising from an acquisition and long-lived assets, which would be

recognized at fair value if deemed to be impaired or if reclassified as assets held for sale. The fair value in these instances would be determined using Level 3 inputs.

TELA Bio, Inc.

At December 31, 2018, the Company held a $14.1 million investment in convertible preferred B shares of TELA Bio, Inc., or TELA Bio, a privately-held surgical reconstruction company that markets its proprietary OviTex^TM portfolio of products for ventral hernia repair and abdominal wall reconstruction. In June 2019, the Company made an additional cash investment of $1.6 million in TELA Bio’s convertible preferred B shares. In September 2019, the investment was deemed to be impaired when an offer was made to sell the Company’s shares in TELA Bio for an amount less than the Company’s carrying amount. The fair value of the investment was based on an initial public offering estimated price range less a discount for a lack of liquidity. The Company recognized an impairment charge of $5.4 million, which was recorded in other, net in its consolidated statements of operations for the three and nine months ended September 30, 2019. In the three and nine months ended September 30, 2018, the Company recorded a loss of $0.9 million on an unexercised purchase option in TELA Bio, which was recorded in other, net in its consolidated statements of operations.

Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments, long-term investments and accounts receivable. The Company maintains its cash and cash equivalents with high-credit quality financial institutions. Such amounts may exceed federally-insured limits.

As of September 30, 2019, three wholesalers each accounted for over 10% of the Company’s accounts receivable, at 34%, 30% and 29%, respectively. At December 31, 2018, three wholesalers each accounted for over 10% of the Company’s accounts receivable, at 32%, 32% and 29%, respectively. For additional information regarding the Company’s wholesalers, see Note 2, Summary of Significant Accounting Policies. Revenues are primarily derived from major wholesalers and pharmaceutical companies that generally have significant cash resources. The Company performs ongoing credit evaluations of its customers as warranted and generally does not require collateral. Allowances for doubtful accounts receivable are maintained based on historical payment patterns, aging of accounts receivable and the Company’s actual write-off history. As of September 30, 2019 and December 31, 2018, no allowances for doubtful accounts were deemed necessary by the Company on its accounts receivable.

STOCK PLANS

9 Months Ended

Sep. 30, 2019

Stockholders' Equity Note [Abstract]

STOCK PLANS

Stock Incentive Plans

In June 2019, the Company’s stockholders approved the Amended and Restated 2011 Stock Incentive Plan, or 2011 Plan. The 2011 Plan was amended to increase the number of shares of common stock authorized for issuance as equity awards under the plan by 3,000,000 shares.

Stock-Based Compensation

The Company recognized stock-based compensation expense in the periods presented as follows (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Cost of goods sold	$	1,243	$	1,179	$	3,490	$	3,431
Research and development	1,297		1,122		3,772		2,770
Selling, general and administrative	6,704		5,807		17,199		17,338
Total	$	9,244	$	8,108	$	24,461	$	23,539

Stock-based compensation from:
Stock options (employee awards)	$	6,257	$	5,270	$	16,509	$	16,452
Stock options (consultant awards)	161		209		408		449
Restricted stock units (employee awards)	2,639		2,479		6,950		6,088
Employee stock purchase plan	187		150		594		550
Total	$	9,244	$	8,108	$	24,461	$	23,539

Equity Awards

The following tables contain information about the Company’s stock option and restricted stock unit, or RSU, activity for the nine months ended September 30, 2019:



Stock Options	Number of Options		Weighted Average Exercise Price
Outstanding at December 31, 2018	5,722,818		$	41.69
Granted	1,792,978		42.81
Exercised	(251,169	)	19.88
Forfeited	(258,353	)	41.51
Expired	(125,316	)	59.20
Outstanding at September 30, 2019	6,880,958		42.46



Restricted Stock Units	Number of Units		Weighted Average Grant Date Fair Value
Unvested at December 31, 2018	577,964		$	42.14
Granted	303,168		43.57
Vested	(190,586	)	45.56
Forfeited	(49,611	)	41.04
Unvested at September 30, 2019	640,935		41.88

The weighted average fair value of stock options granted during the nine months ended September 30, 2019 was $20.97 per share. The fair values of stock options granted were estimated using the Black-Scholes option valuation model with the following weighted average assumptions:



Black-Scholes Weighted Average Assumption		Nine Months Ended September 30, 2019
Expected dividend yield		None
Risk-free interest rate		2.02%
Expected volatility		53.88%
Expected term of options		5.22 years

Employee Stock Purchase Plan

The Company’s 2014 Employee Stock Purchase Plan, or ESPP, features two six-month offering periods per year, running from January 1to June 30 and July 1 to December 31. Under the ESPP, employees may elect to contribute after-tax earnings to purchase shares at 85% of the closing fair market value of the Company’s common stock on either the offering date or the purchase date, whichever is less. During the nine months ended September 30, 2019, 35,766 shares were purchased and issued through the ESPP.

STOCKHOLDERS' EQUITY

9 Months Ended

Sep. 30, 2019

Stockholders' Equity Note [Abstract]

Stockholders' Equity

STOCKHOLDERS’ EQUITY

Accumulated Other Comprehensive Income (Loss)

The following table illustrates the changes in the balances of the Company’s accumulated other comprehensive income (loss) for the periods presented (in thousands):



	Nine Months Ended September 30,
Net unrealized gains (losses) from available for sale investments:	2019			2018
Balance at beginning of period	$	(280	)	$	(454	)
Other comprehensive income before reclassifications	727			213
Amounts reclassified from accumulated other comprehensive income (loss)	—			—
Balance at end of period	$	447		$	(241	)

NET INCOME (LOSS) PER SHARE

9 Months Ended

Sep. 30, 2019

Earnings Per Share [Abstract]

NET INCOME (LOSS) PER SHARE

Basic net income (loss) per share is calculated by dividing the net income (loss) attributable to common shares by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per common share is calculated by dividing the net income (loss) attributable to common shares by the weighted average number of common shares outstanding plus dilutive potential common shares outstanding during the period. Potential common shares include the shares of common stock issuable upon the exercise of outstanding stock options, the vesting of RSUs, the purchase of shares from the ESPP (using the treasury stock method) as well as the conversion of the excess conversion value on the 2022 Notes. As discussed in Note 9, Debt, the Company has the option to pay cash for the aggregate principal amount due upon the conversion of its 2022 Notes. Since it is the Company’s intent to settle the principal amount of its 2022 Notes in cash, the potentially dilutive effect of such notes on net income (loss) per share is computed under the treasury stock method. The Company settled the principal and conversion premium of its 2019 Notes in cash.

Potential common shares are excluded from the diluted net income (loss) per share computation to the extent they would be antidilutive. Because the Company reported a net loss for each of the three and nine month periods ended September 30, 2019 and 2018, no potentially dilutive securities have been included in the computation of diluted net loss per share for those periods.

The following table sets forth the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2019 and 2018 (in thousands, except per share amounts):



	Three Months Ended September 30,						Nine Months Ended September 30,
	2019			2018			2019			2018
Numerator:
Net loss	$	(6,087	)	$	(640	)	$	(6,128	)	$	(8,756	)
Denominator:
Weighted average common shares outstanding—basic and diluted	41,645			40,995			41,423			40,833
Net loss per share:
Basic and diluted net loss per common share	$	(0.15	)	$	(0.02	)	$	(0.15	)	$	(0.21	)

The following outstanding stock options, RSUs and ESPP purchase options are antidilutive in the periods presented (in thousands):



	Three Months Ended September 30,		Nine Months Ended September 30,
	2019	2018	2019	2018
Weighted average number of stock options	5,443	5,988	4,816	5,392
Weighted average number of RSUs	266	618	154	528
Weighted average ESPP purchase options	33	29	23	32
Total	5,742	6,635	4,993	5,952

INCOME TAXES

9 Months Ended

Sep. 30, 2019

Income Tax Disclosure [Abstract]

TAXES

INCOME TAXES

Income (loss) before income taxes is as follows (in thousands):



	Three Months Ended September 30,						Nine Months Ended September 30,
	2019			2018			2019			2018
Income (loss) before income taxes:
Domestic	$	(3,234	)	$	1,839		$	2,345		$	(7,382	)
Foreign	(2,582		)	(2,541		)	(9,552		)	(1,366		)
Total loss before income taxes	$	(5,816	)	$	(702	)	$	(7,207	)	$	(8,748	)

For the three months ended September 30, 2019 and 2018, the Company recorded income tax expense of $0.3 million and an income tax benefit of $0.1 million, respectively. For the nine months ended September 30, 2019 and 2018, the Company recorded an income tax benefit of $1.1 million and an income tax expense of less than $0.1 million, respectively. The income tax benefit for the nine months ended September 30, 2019 is primarily related to the MyoScience Acquisition and a $1.8 million reduction in the Company’s valuation allowance on its deferred tax assets due to the MyoScience Acquisition, partially offset by current state income taxes. Due to net operating losses, or NOLs, carried forward, and the repeal of the corporate minimum tax, no current federal income tax expense was recorded for 2018 or 2019. The utilization of the Company’s NOLs has not resulted in any deferred federal tax expense because there was a full valuation allowance recorded with respect to the NOLs.

ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET

9 Months Ended

Sep. 30, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

(e) Discontinuation

In June 2017, the Company’s board of directors approved the discontinuation of all future production of DepoCyt^® (U.S. and Canada) and DepoCyte^® (European Union) due to persistent technical issues specific to the DepoCyt(e) manufacturing process. As of June 30, 2017, the Company had ceased all production of DepoCyt(e). Cash payments related to the DepoCyt(e) manufacturing facility are expected to continue through the end of its lease term in August 2020.

In April 2018, the Company received formal notice of the termination of a Supply Agreement and a Distribution Agreement (and all related agreements as subsequently amended) from Mundipharma International Corporation Limited and Mundipharma Medical Company, respectively (collectively, “Mundipharma”). The Company is currently engaged in settlement discussions with Mundipharma.

Summary of Acquisition-Related Restructuring Activities and DepoCyt(e) Discontinuation Costs

At January 1, 2019, there was a balance sheet reclassification from the lease cost reserves related to the DepoCyt(e) discontinuation to lease liabilities in the amount of $1.5 million, recognized as part of the transition to the ASU 2016-02. See Note 2, Summary of Significant Accounting Policies, for more information. The Company’s acquisition-related restructuring and DepoCyt(e) discontinuation costs as of September 30, 2019 are summarized below (in thousands):



	Acquisition-Related Separation Costs			Acquisition-Related Asset Write-Downs			DepoCyt(e) Lease Costs			Asset Retirement Obligations, Other Restructuring and Discontinuation Costs			Total
Balance at December 31, 2018	$	—		$	—		$	1,970		$	282		$	2,252
Charges incurred	480			193			—			167			840
Cash payments made	(321		)	—			—			(307		)	(628		)
Other, including non-cash activity	—			(193		)	—			—			(193		)
Reclassifications	—			—			(1,970		)	455			(1,515		)
Balance at September 30, 2019	$	159		$	—		$	—		$	597		$	756

COMMITMENTS AND CONTINGENCIES	9 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Litigation From time to time, the Company has been and may again become involved in legal proceedings arising in the ordinary course of its business, including those related to patents, product liability and government investigations. Except as described below, the Company is not presently a party to any legal proceedings which it believes to be material, and is not aware of any pending or threatened litigation against the Company which it believes could have a material adverse effect on its business, operating results, financial condition or cash flows. In April 2015, the Company received a subpoena from the U.S. Department of Justice, U.S. Attorney’s Office for the District of New Jersey, requiring the production of a broad range of documents pertaining to marketing and promotional practices related to EXPAREL. The Company is cooperating with the government’s inquiry. The Company can make no assurances as to the time or resources that will need to be devoted to this inquiry or its final outcome, or the impact, if any, of this inquiry or any proceedings on its business, financial condition, results of operations and cash flows.

Subsequent Events (Notes)	3 Months Ended
Subsequent Events (Notes)	Dec. 31, 2019
Subsequent Event [Line Items]
Subsequent Events [Text Block]	NOTE 17—SUBSEQUENT EVENTS Contingent Consideration In November 2019, the Company received new regulatory information and now expects to achieve an additional $10.0 million contingent regulatory milestone related to the MyoScience Acquisition, which can be made in either cash or shares of the Company’s common stock, or a combination thereof, at the election of MyoScience shareholders. As a result, in the fourth quarter of 2019, the Company expects to record a charge to acquisition-related charges of approximately $9.0 million. For more information regarding contingent milestone payments related to the MyoScience Acquisition, refer to Note 4, MyoScience Acquisition.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Basis of Presentation and Principles of Consolidation

The results of operations for these interim periods are not necessarily indicative of results that may be expected for any other interim periods or for the full year.

Concentration of Major Customers



	Three Months Ended September 30,		Nine Months Ended September 30,
	2019	2018	2019	2018
Largest wholesaler	34%	34%	34%	34%
Second largest wholesaler	29%	30%	29%	30%
Third largest wholesaler	27%	26%	26%	26%
Total	90%	90%	89%	90%

Recent Accounting Pronouncements

Recently Adopted Accounting Pronouncements

Recent Accounting Pronouncements Not Adopted as of September 30, 2019

Leases

Acquisitions [Policy Text Block]

Acquisitions

Contingent Consideration [Policy Text Block]

Contingent Consideration

Intangible Assets, Finite-Lived, Policy [Policy Text Block]

Intangible Assets

Segment Reporting, Policy [Policy Text Block]

Segment Reporting

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Schedule of percentage of revenue comprised by the three largest customers (i.e. wholesalers or commercial partners)

The table below includes the percentage of revenue comprised by the Company’s three largest wholesalers in each period presented:



	Three Months Ended September 30,		Nine Months Ended September 30,
	2019	2018	2019	2018
Largest wholesaler	34%	34%	34%	34%
Second largest wholesaler	29%	30%	29%	30%
Third largest wholesaler	27%	26%	26%	26%
Total	90%	90%	89%	90%

REVENUE (Tables)

9 Months Ended

Sep. 30, 2019

Revenue from Contract with Customer [Abstract]

Disaggregated Revenue

The following table represents disaggregated net product sales in the periods presented as follows (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
Net Product Sales	2019		2018		2019		2018
EXPAREL / bupivacaine liposome injectable suspension	$	101,711	$	82,708	$	292,406	$	237,713
iovera°	2,639		—		4,674		—
Total net product sales	$	104,350	$	82,708	$	297,080	$	237,713

MYOSCIENCE ACQUISITION (Tables)

9 Months Ended

Sep. 30, 2019

Business Combinations [Abstract]

Schedule of Business Acquisition

CryoTech results from the acquisition date of April 10, 2019 through September 30, 2019, which are included in the condensed consolidated statements of operations, are as follows (in thousands):



Classification in Condensed Consolidated Statements of Operations	Acquisition Date Through September 30, 2019
Total revenues	$	4,674
Net loss	$	(5,555	)

The total consideration for the MyoScience Acquisition was $147.5 million, which consisted of the following (in thousands):



Purchase Price	Amount
Cash paid, adjusted for working capital items	$	119,038
Fair value of contingent consideration	28,470
Total	$	147,508

The following tables set forth the preliminary allocation of the MyoScience Acquisition purchase price to the estimated fair value of the net assets acquired at the acquisition date (in thousands):



	Amounts Recognized at the Acquisition Date (Unaudited)
ASSETS ACQUIRED
Current assets	$	5,275
Non-current assets (other than intangible assets)	1,044
Intangible assets (excluding goodwill)	110,090
Total assets acquired (excluding goodwill)	$	116,409

LIABILITIES ASSUMED
Current liabilities	$	4,436
Deferred tax liabilities, net	1,828
Other non-current liabilities	144
Total liabilities assumed	6,408
Total identifiable net assets acquired	110,001
Goodwill	37,507
Total consideration transferred	$	147,508

Unaudited Pro Forma Summary of Operations



	Three Months Ended September 30,			Nine Months Ended September 30,
	2018			2019			2018
Total revenues	$	84,916		$	301,051		$	245,721
Net loss	$	(6,944	)	$	(10,633	)	$	(27,663	)
Pro forma basic and diluted net loss per share	$	(0.17	)	$	(0.26	)	$	(0.68	)

INVENTORIES (Tables)

9 Months Ended

Sep. 30, 2019

Inventory Disclosure [Abstract]

Schedule of components of inventories

The components of inventories, net are as follows (in thousands):



	September 30,		December 31,
	2019		2018
Raw materials	$	18,798	$	19,193
Work-in-process	17,472		9,711
Finished goods	23,968		19,665
Total	$	60,238	$	48,569

FIXED ASSETS (Tables)

9 Months Ended

Sep. 30, 2019

Property, Plant and Equipment [Abstract]

Schedule of fixed assets summarized by major category

Fixed assets, net, summarized by major category, consist of the following (in thousands):



	September 30,			December 31,
	2019			2018
Machinery and equipment	$	68,342		$	67,431
Leasehold improvements	60,355			57,955
Computer equipment and software	8,381			8,131
Office furniture and equipment	1,625			1,548
Construction in progress	38,421			35,163
Total	177,124			170,228
Less: accumulated depreciation	(72,268		)	(61,558		)
Fixed assets, net	$	104,856		$	108,670

LEASES (Tables)

9 Months Ended

Sep. 30, 2019

Leases [Abstract]

Summary of operating lease cost and other operating lease information

The weighted average remaining lease term and the weighted average discount rate are summarized as follows:



		September 30, 2019
Weighted average remaining lease term		9.66 years
Weighted average discount rate		7.62%

Total operating lease costs are as follows (in thousands):



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
Operating Lease Costs	2019		2018		2019		2018
Fixed lease costs	$	1,585	$	2,659	4,544		5,750
Variable lease costs	403		495		1,233		1,305
Total	$	1,988	$	3,154	$	5,777	$	7,055

Supplemental cash flow information related to operating leases is as follows (in thousands):



	Nine Months Ended
	September 30, 2019
Cash paid for operating lease liabilities, net of lease incentive	$	5,247
Right-of-use assets recorded in exchange for lease obligations	$	38,419

Schedule of maturities of operating lease liabilities

Maturities of the Company’s operating lease liabilities are as follows (in thousands):



Year	Aggregate Minimum Payments Due
2019 (remaining three months)	$	2,039
2020	7,662
2021	5,359
2022	5,486
2023	5,616
2024 through 2030	37,208
Total lease payments	63,370

Less: imputed interest	(19,445		)
Total operating lease liabilities	$	43,925

Schedule of maturities of operating lease liabilities



Year	Aggregate Minimum Payments Due
2019 (remaining three months)	$	27
2020	2,607
2021	4,878
2022	4,937
2023	5,081
2024 through 2030	35,848
Total future lease payments	$	53,378

Schedule of maturities of operating lease liabilities

As of December 31, 2018, aggregate annual minimum payments due under the Company’s lease obligations were as follows (in thousands):



Year	Aggregate Minimum Payments Due
2019	$	8,140
2020	7,621
2021	5,295
2022	5,417
2023	5,543
2024 through 2030	14,329
Total	$	46,345

GOODWILL AND INTANGIBLE ASSETS (Tables)

9 Months Ended

Sep. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

The change in the carrying value of the Company’s goodwill is summarized as follows (in thousands):



	Carrying Value of Goodwill
Balance at December 31, 2018	$	62,040
Goodwill arising from the MyoScience Acquisition	37,507
Balance at September 30, 2019	$	99,547

DEBT (Tables)

9 Months Ended

Sep. 30, 2019

Debt Disclosure [Abstract]

Schedule of composition of the Company's debt and financing obligations

The total debt composition of the 2022 Notes is as follows (in thousands):



	September 30,			December 31,
	2019			2018
2.375% convertible senior notes due 2022	$	345,000		$	345,000
Deferred financing costs	(4,577		)	(5,850		)
Discount on debt	(38,342		)	(48,558		)
Total debt, net of debt discount and deferred financing costs	$	302,081		$	290,592

Schedule of total interest expense recognized related to the Notes

The following table sets forth the total interest expense recognized in the periods presented (dollar amounts in thousands):



	Three Months Ended September 30,						Nine Months Ended September 30,
	2019			2018			2019			2018
Contractual interest expense	$	2,048		$	2,051		$	6,146		$	6,153
Amortization of debt issuance costs	429			411			1,273			1,219
Amortization of debt discount	3,467			3,228			10,216			9,512
Capitalized interest (Note 6)	(4		)	(48		)	(4		)	(689		)
Total	$	5,940		$	5,642		$	17,631		$	16,195

Effective interest rate on convertible senior notes	7.81		%	7.81		%	7.81		%	7.81		%

FINANCIAL INSTRUMENTS (Tables)

9 Months Ended

Sep. 30, 2019

Fair Value Disclosures [Abstract]

Schedule of carrying amount and fair value of the long-term debt

The carrying amount and fair values of the Company’s convertible senior notes and acquisition-related contingent consideration are as follows (in thousands):



Financial Liabilities	Carrying Value		Fair Value Measurements Using
September 30, 2019	Carrying Value		Level 1		Level 2		Level 3
2.375% convertible senior notes due 2022 ⁽¹⁾⁽²⁾	$	302,081	$	—	$	340,472	$	—
Acquisition-related contingent consideration ⁽³⁾	$	35,797	$	—	$	—	$	35,797

(2) Reported at historical cost.

(3) Reported at fair value on a recurring basis.

Schedule of key assumptions used in the valuation of contingent consideration

The following table includes the key assumptions used in the valuation of the Company’s contingent consideration:



Assumption		Ranges Utilized as of September 30, 2019
Discount rates		5.29% to 5.64%
Probabilities of payment for regulatory milestones		0% to 100% ⁽¹⁾
Projected years of payment for regulatory milestones		2019 to 2023
Projected years of payment for commercial milestones		Up to 4.25 years

(1) One of the regulatory milestones was met during the three months ended September 30, 2019, requiring a payment in the amount of $7.0 million to be made in the fourth quarter of 2019.

Schedule of change in contingent consideration recorded at fair value using Level 3 measurements

The change in the Company’s contingent consideration recorded at fair value using Level 3 measurements is as follows (in thousands):



	Fair Value
Balance at December 31, 2018	$	—
New financial liabilities entered into on date of MyoScience Acquisition (April 9, 2019)	28,470
Fair value adjustments and accretion	7,327
Balance at September 30, 2019	$	35,797

Schedule of short-term investments

The following summarizes the Company’s investments at September 30, 2019 and December 31, 2018 (in thousands):



September 30, 2019 Investments	Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value (Level 2)
Short-term:
Asset-backed securities	$	29,044	$	60	$	—		$	29,104
Commercial paper	34,788		41		—			34,829
Corporate bonds	116,273		299		—			116,572
Subtotal	180,105		400		—			180,505
Long-term:
Asset-backed securities	16,518		23		(7		)	16,534
Corporate bonds	54,012		48		(17		)	54,043
Subtotal	70,530		71		(24		)	70,577
Total	$	250,635	$	471	$	(24	)	$	251,082



December 31, 2018 Investments	Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value (Level 2)
Short-term:
Asset-backed securities	$	34,873	$	—	$	(33	)	$	34,840
Commercial paper	45,035		—		(30		)	45,005
Corporate bonds	171,289		—		(206		)	171,083
Subtotal	251,197		—		(269		)	250,928
Long-term:
Asset-backed securities	9,383		5		—			9,388
Corporate bonds	16,499		—		(16		)	16,483
Subtotal	25,882		5		(16		)	25,871
Total	$	277,079	$	5	$	(285	)	$	276,799

STOCK PLANS (Tables)

9 Months Ended

Sep. 30, 2019

Stockholders' Equity Note [Abstract]

Schedule of recognized stock-based compensation in consolidated statements of operations

The Company recognized stock-based compensation expense in the periods presented as follows (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Cost of goods sold	$	1,243	$	1,179	$	3,490	$	3,431
Research and development	1,297		1,122		3,772		2,770
Selling, general and administrative	6,704		5,807		17,199		17,338
Total	$	9,244	$	8,108	$	24,461	$	23,539

Stock-based compensation from:
Stock options (employee awards)	$	6,257	$	5,270	$	16,509	$	16,452
Stock options (consultant awards)	161		209		408		449
Restricted stock units (employee awards)	2,639		2,479		6,950		6,088
Employee stock purchase plan	187		150		594		550
Total	$	9,244	$	8,108	$	24,461	$	23,539

Schedule of the Company's stock option activity and related information

The following tables contain information about the Company’s stock option and restricted stock unit, or RSU, activity for the nine months ended September 30, 2019:



Stock Options	Number of Options		Weighted Average Exercise Price
Outstanding at December 31, 2018	5,722,818		$	41.69
Granted	1,792,978		42.81
Exercised	(251,169	)	19.88
Forfeited	(258,353	)	41.51
Expired	(125,316	)	59.20
Outstanding at September 30, 2019	6,880,958		42.46



Restricted Stock Units	Number of Units		Weighted Average Grant Date Fair Value
Unvested at December 31, 2018	577,964		$	42.14
Granted	303,168		43.57
Vested	(190,586	)	45.56
Forfeited	(49,611	)	41.04
Unvested at September 30, 2019	640,935		41.88

STOCKHOLDERS' EQUITY (Tables)

9 Months Ended

Sep. 30, 2019

Stockholders' Equity Note [Abstract]

Schedule of accumulated other comprehensive income (loss)

The following table illustrates the changes in the balances of the Company’s accumulated other comprehensive income (loss) for the periods presented (in thousands):



	Nine Months Ended September 30,
Net unrealized gains (losses) from available for sale investments:	2019			2018
Balance at beginning of period	$	(280	)	$	(454	)
Other comprehensive income before reclassifications	727			213
Amounts reclassified from accumulated other comprehensive income (loss)	—			—
Balance at end of period	$	447		$	(241	)

NET INCOME (LOSS) PER SHARE (Tables)

9 Months Ended

Sep. 30, 2019

Earnings Per Share [Abstract]

Schedule of computation of basic and diluted loss per share

The following table sets forth the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2019 and 2018 (in thousands, except per share amounts):



	Three Months Ended September 30,						Nine Months Ended September 30,
	2019			2018			2019			2018
Numerator:
Net loss	$	(6,087	)	$	(640	)	$	(6,128	)	$	(8,756	)
Denominator:
Weighted average common shares outstanding—basic and diluted	41,645			40,995			41,423			40,833
Net loss per share:
Basic and diluted net loss per common share	$	(0.15	)	$	(0.02	)	$	(0.15	)	$	(0.21	)

Schedule of potential dilutive effect of the securities excluded from the calculation of diluted loss per share

The following outstanding stock options, RSUs and ESPP purchase options are antidilutive in the periods presented (in thousands):



	Three Months Ended September 30,		Nine Months Ended September 30,
	2019	2018	2019	2018
Weighted average number of stock options	5,443	5,988	4,816	5,392
Weighted average number of RSUs	266	618	154	528
Weighted average ESPP purchase options	33	29	23	32
Total	5,742	6,635	4,993	5,952

INCOME TAXES (Tables)

9 Months Ended

Sep. 30, 2019

Income Tax Disclosure [Abstract]

Schedule of Income before Income Tax, Domestic and Foreign

Income (loss) before income taxes is as follows (in thousands):



	Three Months Ended September 30,						Nine Months Ended September 30,
	2019			2018			2019			2018
Income (loss) before income taxes:
Domestic	$	(3,234	)	$	1,839		$	2,345		$	(7,382	)
Foreign	(2,582		)	(2,541		)	(9,552		)	(1,366		)
Total loss before income taxes	$	(5,816	)	$	(702	)	$	(7,207	)	$	(8,748	)

ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET (Tables)

9 Months Ended

Sep. 30, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]



	Acquisition-Related Separation Costs			Acquisition-Related Asset Write-Downs			DepoCyt(e) Lease Costs			Asset Retirement Obligations, Other Restructuring and Discontinuation Costs			Total
Balance at December 31, 2018	$	—		$	—		$	1,970		$	282		$	2,252
Charges incurred	480			193			—			167			840
Cash payments made	(321		)	—			—			(307		)	(628		)
Other, including non-cash activity	—			(193		)	—			—			(193		)
Reclassifications	—			—			(1,970		)	455			(1,515		)
Balance at September 30, 2019	$	159		$	—		$	—		$	597		$	756

DESCRIPTION OF BUSINESS (Details)	9 Months Ended
DESCRIPTION OF BUSINESS (Details)	Sep. 30, 2019 product
Sales Revenue, Net \| Product Concentration Risk
Concentration Risk [Line Items]
Concentration of products (in products)	2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	3 Months Ended		9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019 customer segment	Sep. 30, 2018
Concentration of Major Customers
Number of reportable segments \| segment			1
Concentration risk by major customer
Concentration of Major Customers
Number of major customers \| customer			3
Net revenue \| Concentration risk by major customer
Concentration of Major Customers
Percentage of revenue from customers to total revenue	90.00%	90.00%	89.00%	90.00%
Net revenue \| Concentration risk by major customer \| Largest wholesaler
Concentration of Major Customers
Percentage of revenue from customers to total revenue	34.00%	34.00%	34.00%	34.00%
Net revenue \| Concentration risk by major customer \| Second largest wholesaler
Concentration of Major Customers
Percentage of revenue from customers to total revenue	29.00%	30.00%	29.00%	30.00%
Net revenue \| Concentration risk by major customer \| Third largest wholesaler
Concentration of Major Customers
Percentage of revenue from customers to total revenue	27.00%	26.00%	26.00%	26.00%

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES New Accounting Pronouncements or change in Accounting Policy (Details) - USD ($) $ in Thousands	Jan. 01, 2019	Sep. 30, 2019	Dec. 31, 2018
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total operating lease liabilities		$ 43,925
ROU asset		$ 35,756	$ 0
Accounting Standards Update 2016-02
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total operating lease liabilities	$ 36,500
ROU asset	27,600
Cumulative-effect adjustment to retained earnings	$ 200

REVENUE (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
REVENUE (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Disaggregation of Revenue [Line Items]
Total net product sales	$ 104,350	$ 82,708	$ 297,080	$ 237,713
EXPAREL/bupivacaine liposome injectable suspension [Member]
Disaggregation of Revenue [Line Items]
Total net product sales	101,711	82,708	292,406	237,713
iovera°
Disaggregation of Revenue [Line Items]
Total net product sales	$ 2,639	$ 0	$ 4,674	$ 0
Minimum
Disaggregation of Revenue [Line Items]
Accounts Receivable, Additional Narrative Disclosure			P0D
Maximum
Disaggregation of Revenue [Line Items]
Accounts Receivable, Additional Narrative Disclosure			P37D

- Definition

Further narrative disclosure of claims held for amounts due a company. Examples include trade accounts receivables, notes receivables, loans receivables, etc.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84173941&loc=d3e5130-111524

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 860
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109247956&loc=d3e107425-111719

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=84173941&loc=d3e5111-111524

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82891408&loc=d3e4428-111522

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=84173941&loc=d3e5144-111524

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=84173941&loc=d3e5074-111524

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84173941&loc=d3e5066-111524

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=84173941&loc=d3e5086-111524

+ Details

MYOSCIENCE ACQUISITION (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
MYOSCIENCE ACQUISITION (Details) - USD ($) $ in Thousands	Apr. 09, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Business Acquisition [Line Items]
Income (loss) before income taxes		$ (5,816)	$ (702)	$ (7,207)	$ (8,748)
Valuation allowance on deferred tax assets		1,800		1,800
Acquisition-related contingent consideration		7,000		7,000
Myoscience Acquisition
Business Acquisition [Line Items]
Initial cash payment		120,000
Fair value of contingent consideration	$ 28,470
Contingent consideration		100,000
Contingent consideration maximum amount payable in shares	$ 25,000
Payment term	60 days
Total consideration transferred		147,508
Net income (loss)			$ (6,944)	(10,633)	$ (27,663)
Acquisition-related contingent consideration		35,800		35,800
Scenario, Forecast \| Achievement of Regulatory Milestone
Business Acquisition [Line Items]
Acquisition-related contingent consideration		$ 5,000		$ 5,000

MYOSCIENCE ACQUISITION - Schedule of Business Acquisition (Details) - USD ($) $ in Thousands		3 Months Ended			9 Months Ended
	Apr. 09, 2019	Sep. 30, 2019	Jun. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Acquisition-related contingent consideration		$ 7,000			$ 7,000
Goodwill		99,547			99,547			$ 62,040
Revenues		104,685		$ 83,448	298,602	$ 242,163
Myoscience Acquisition
Business Acquisition [Line Items]
Acquisition-related contingent consideration		35,800			35,800
Goodwill, Translation and Purchase Accounting Adjustments		1,000
Cash paid, adjusted for working capital items	$ 119,038
Fair value of contingent consideration	28,470
Total		147,508
Current assets	5,275
Non-current assets (other than intangible assets)	1,044
Intangible assets (excluding goodwill)	110,090
Total assets acquired (excluding goodwill)	116,409
Current liabilities	4,436
Deferred tax liabilities, net	1,828
Other non-current liabilities	144
Total liabilities assumed	6,408
Total identifiable net assets acquired	110,001
Goodwill	37,507
Total consideration transferred	$ 147,508
Revenues			$ 4,674
Net loss			$ (5,555)
Achievement of Regulatory Milestone [Domain]
Business Acquisition [Line Items]
Acquisition-related contingent consideration		7,000			7,000
Scenario, Forecast \| Achievement of Regulatory Milestone [Member]
Business Acquisition [Line Items]
Acquisition-related contingent consideration		$ 5,000			$ 5,000
Scenario, Forecast \| Subsequent Event \| Achievement of Development and Commercial Milestones
Business Acquisition [Line Items]
Acquisition-related contingent consideration							$ 10,000

MYOSCIENCE ACQUISITION - Unaudited Pro Forma Summary of Operations (Details) - Myoscience Acquisition - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Business Acquisition [Line Items]
Total revenues	$ 84,916	$ 301,051	$ 245,721
Net income (loss)	$ (6,944)	$ (10,633)	$ (27,663)
Business Acquisition, Pro Forma Earnings Per Share, Basic And Diluted	$ (170)	$ (260)	$ (680)

INVENTORIES (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Raw materials	$ 18,798	$ 19,193
Work-in-process	17,472	9,711
Finished goods	23,968	19,665
Total	60,238	$ 48,569
Maximum [Member]
Inventory Valuation Reserves	$ 10,500

FIXED ASSETS (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
FIXED ASSETS (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
FIXED ASSETS
Total	$ 177,124		$ 177,124		$ 170,228
Less: accumulated depreciation	(72,268)		(72,268)		(61,558)
Fixed assets, net	104,856		104,856		108,670
Depreciation expense	3,600	$ 3,500	10,700	$ 9,100
Capitalized interest (Note 4)		$ 100		$ 700
Foreign property, plant and equipment, net	65,100		65,100		64,600
Increase (Decrease) in Asset Retirement Obligations			300
Asset Retirement Obligation, Accretion Expense	100		200
Machinery and equipment
FIXED ASSETS
Total	68,342		68,342		67,431
Leasehold improvements
FIXED ASSETS
Total	60,355		60,355		57,955
Computer equipment and software
FIXED ASSETS
Total	8,381		8,381		8,131
Office furniture and equipment
FIXED ASSETS
Total	1,625		1,625		1,548
Construction in progress
FIXED ASSETS
Total	38,421		38,421		$ 35,163
Capitalized interest (Note 4)	$ 100		$ 100

LEASES -Narrative (Details)	9 Months Ended
LEASES -Narrative (Details)	Sep. 30, 2019 ft²
Lease term renewal	4 years
Weighted average remaining lease term	9 years 7 months 28 days
Weighted average discount rate	7.62%
Minimum
Term of contract	1 year
Maximum
Term of contract	11 years
Fremont, California \| Building
Operating lease, area (in sq ft)	20,000

LEASES -Summary of operating lease cost and other operating lease information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Operating lease costs:
Fixed lease costs	$ 1,585	$ 2,659	$ 4,544	$ 5,750
Variable lease costs	403	495	1,233	1,305
Total	$ 1,988	$ 3,154	5,777	$ 7,055
Cash paid for operating lease liabilities, net of lease incentive
Right-of-use assets recorded in exchange for lease obligations			$ 5,247
Weighted average remaining lease term	9 years 7 months 28 days		9 years 7 months 28 days
Weighted average discount rate	7.62%		7.62%
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability			$ 38,419

LEASES -Schedule of maturities of operating lease liabilities (Details) $ in Thousands	Sep. 30, 2019 USD ($)
Leases [Abstract]
2019 (remaining three months)	$ 2,039
2020	7,662
2021	5,359
2022	5,486
2023	5,616
2024 through 2030	37,208
Total lease payments	63,370
Less: imputed interest	(19,445)
Total operating lease liabilities	$ 43,925

LEASES -Schedule of maturities of operating lease liabilities (lease not yet commenced) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019 USD ($) contract
Leases [Abstract]
Number of leases not yet commenced \| contract	3
2019 (remaining three months)	$ 27
2020	2,607
2021	4,878
2022	4,937
2023	5,081
2024 through 2030	35,848
Total future lease payments	$ 53,378

LEASES -Schedule of maturities of operating lease liabilities (prior year) (Details) $ in Thousands	Dec. 31, 2018 USD ($)
Leases [Abstract]
2019	$ 8,140
2020	7,621
2021	5,295
2022	5,417
2023	5,543
2024 through 2030	14,329
Total	$ 46,345

GOODWILL AND INTANGIBLE ASSETS (Details) - USD ($)	3 Months Ended		9 Months Ended
GOODWILL AND INTANGIBLE ASSETS (Details) - USD ($)	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Apr. 09, 2019	Dec. 31, 2018
Goodwill
Goodwill recorded in connection with the acquisition	$ 99,547,000		$ 99,547,000			$ 62,040,000
Intangible assets, net	106,354,000		106,354,000			0
Amortization of acquired intangible assets	1,967,000	$ 0	3,736,000	$ 0
Amortization expense, remainder of fiscal year	2,000,000.0		2,000,000.0
Amortization expense, 2020-2032	7,900,000		7,900,000
Amortization expense, 2033	2,200,000		2,200,000
Upon first commercial sale in the United States
Goodwill
Milestone payments for EXPAREL agreed in connection with acquisition	10,000,000.0		10,000,000.0
Upon first commercial sale in a major EU country (United Kingdom, France, Germany, Italy and Spain)
Goodwill
Milestone payments for EXPAREL agreed in connection with acquisition	4,000,000.0		4,000,000.0
When annual net sales collected reach $100.0 million
Goodwill
Milestone payments for EXPAREL agreed in connection with acquisition	8,000,000.0		8,000,000.0
Annual net sales threshold	100,000,000.0		100,000,000.0
When annual net sales collected reach $250.0 million
Goodwill
Milestone payments for EXPAREL agreed in connection with acquisition	8,000,000.0		8,000,000.0
Annual net sales threshold	250,000,000.0		250,000,000.0
When annual net sales collected reach $500.0 million
Goodwill
Milestone payments for EXPAREL agreed in connection with acquisition	32,000,000.0		32,000,000.0
Annual net sales threshold	$ 500,000,000.0		$ 500,000,000.0
Skye Pharma Holding Inc.
Goodwill
Total Milestone Payments Yet to be Paid for Sale of Product in Connection with Acquisition						$ 36,000,000.0
Myoscience Acquisition
Goodwill
Goodwill recorded in connection with the acquisition					$ 37,507,000

GOODWILL AND INTANGIBLE ASSETS - Goodwill Rollforward (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019 USD ($)
Goodwill [Roll Forward]
Balance at December 31, 2018	$ 62,040
Goodwill arising from the MyoScience Acquisition	37,507
Balance at September 30, 2019	$ 99,547

GOODWILL AND INTANGIBLE ASSETS - Schedule of Intangible Assets (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization of acquired intangible assets	$ 1,967,000	$ 0	$ 3,736,000	$ 0
Gross Carrying Value	110,090,000		110,090,000
Accumulated Amortization	(3,736,000)		(3,736,000)
Intangible Assets, Net	106,354,000		106,354,000
Developed technology
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	110,000,000		110,000,000
Accumulated Amortization	(3,732,000)		(3,732,000)
Intangible Assets, Net	106,268,000		$ 106,268,000
Estimated Useful Life			14 years
Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	90,000		$ 90,000
Accumulated Amortization	(4,000)		(4,000)
Intangible Assets, Net	$ 86,000		$ 86,000
Estimated Useful Life			10 years

DEBT (Details) - Unsecured Debt - Convertible Senior Notes Due 2022 - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018	Mar. 13, 2017
Debt Instrument [Line Items]
Stated interest rate (as a percent)	2.375%		2.375%
Convertible senior notes, gross	$ 345,000	$ 345,000
Deferred financing costs	(4,577)	(5,850)
Discount on debt	(38,342)	(48,558)
Total debt, net of debt discount and deferred financing costs	$ 302,081	$ 290,592

DEBT (Details 2) - USD ($)			9 Months Ended
DEBT (Details 2) - USD ($)	Feb. 01, 2019	Mar. 13, 2017	Sep. 30, 2019	Mar. 07, 2017
DEBT AND FINANCING OBLIGATIONS
Settlement period - convertible debt conversion request			40 days
Closing sale price (in dollars per share)			$ 38.07
Repayments of debt	$ 300,000
Repayment of Conversion Premium	$ 200,000
Convertible Senior Notes Due 2022
DEBT AND FINANCING OBLIGATIONS
Initial conversion rate of common stock per $1000 of principal amount of Notes (in shares)		14.9491
Initial conversion price of notes into common stock (in dollars per share)		$ 66.89
Convertible debt, premium on common stock		37.50%
Closing sale price (in dollars per share)				$ 48.65
Debt issuance costs, amortization period		5 years
Convertible Senior Notes Due 2022 \| Conversion terms prior to close of business on business day immediately proceeding October 1, 2021
DEBT AND FINANCING OBLIGATIONS
Convertible debt, common stock closing sales price minimum, number of trading days		20 days
Convertible debt, number of consecutive trading days		30 days
Convertible debt, common stock closing sales price minimum as percentage of conversion price		130.00%
Principal amount used for debt instrument conversion ratio			$ 1,000
Market price per $1000 of principal amount of notes			987
Convertible Senior Notes Due 2022 \| Debt Redemption Terms on or after April 1, 2020
DEBT AND FINANCING OBLIGATIONS
Convertible debt, common stock closing sales price minimum, number of trading days		20 days
Convertible debt, number of consecutive trading days		30 days
Convertible debt, common stock closing sales price minimum as percentage of conversion price		130.00%
Debt Instrument Conversion Obligation Number of Trading Days Prior to Date on which Entity Provides Notice of Redemption		5 days
Debt Instrument, Percentage of Principal Amount for Computation of Redemption Price		100.00%
Convertible Senior Notes Due 2019
DEBT AND FINANCING OBLIGATIONS
Stated interest rate (as a percent)	3.25%
Principal amount used for debt instrument conversion ratio			$ 1,000
Unsecured Debt \| Convertible Senior Notes Due 2022
DEBT AND FINANCING OBLIGATIONS
Debt issued in private placement		$ 345,000,000.0
Stated interest rate (as a percent)		2.375%	2.375%

DEBT (Details 3) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
DEBT (Details 3) - USD ($) $ in Thousands	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Amortization of debt discount			$ 10,216	$ 9,512
Capitalized interest (Note 6)		$ (100)		$ (700)
Effective interest rate on convertible senior notes	7.81%	7.81%	7.81%	7.81%
Convertible Senior Notes Due 2019
Contractual interest expense	$ 2,048	$ 2,051	$ 6,146	$ 6,153
Amortization of debt issuance costs	429	411	1,273	1,219
Amortization of debt discount	3,467	3,228	10,216	9,512
Capitalized interest (Note 6)	(4)	(48)	(4)	(689)
Total	$ 5,940	$ 5,642	$ 17,631	$ 16,195

FINANCIAL INSTRUMENTS (Details)	1 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended
FINANCIAL INSTRUMENTS (Details)	Jun. 30, 2019 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2019 USD ($) customer	Dec. 31, 2017 customer	Dec. 31, 2018 USD ($)
Concentration Risk [Line Items]
Investment in convertible preferred B shares					$ 14,100,000
Additional cash investments in TELA Bio's convertible preferred B shares	$ 1,600,000
Number of major customers \| customer			3	3
Amount of allowance for doubtful accounts		$ 0	$ 0		$ 0
Acquisition-related contingent consideration		7,000,000.0	$ 7,000,000.0
Accounts receivable \| Credit risk \| Major customer one
Concentration Risk [Line Items]
Concentration risk (as a percent)			34.00%	32.00%
Accounts receivable \| Credit risk \| Major customer two
Concentration Risk [Line Items]
Concentration risk (as a percent)			30.00%	32.00%
Accounts receivable \| Credit risk \| Major customer three
Concentration Risk [Line Items]
Concentration risk (as a percent)			29.00%	29.00%
Myoscience Acquisition
Concentration Risk [Line Items]
Acquisition-related contingent consideration		35,800,000	$ 35,800,000
Change in fair value of the contingent consideration since acqusition		$ 7,300,000	$ 7,300,000
Remaining term of the milestone achievement period (in years)			4 years 3 months

FINANCIAL INSTRUMENTS (Details 1) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	Mar. 13, 2017	Sep. 30, 2019	Mar. 07, 2017
Fair Value Measurements
Acquisition-related contingent consideration		$ 7,000
Closing sale price (in dollars per share)		$ 38.07
Convertible Senior Notes Due 2022
Fair Value Measurements
Closing sale price (in dollars per share)			$ 48.65
Initial conversion price of notes into common stock (in dollars per share)	$ 66.89
Convertible Senior Notes Due 2022 \| Level 1
Fair Value Measurements
Convertible senior notes		$ 0
Convertible Senior Notes Due 2022 \| Level 2
Fair Value Measurements
Convertible senior notes		340,472
Convertible Senior Notes Due 2022 \| Level 3
Fair Value Measurements
Convertible senior notes		0
Convertible Senior Notes Due 2022 \| Carrying Value
Fair Value Measurements
Convertible senior notes		302,081
Maximum \| Convertible Senior Notes Due 2022
Fair Value Measurements
Debt Instrument, Convertible, Conversion Premium, Shares	5.2
Myoscience Acquisition
Fair Value Measurements
Acquisition-related contingent consideration		35,800
Myoscience Acquisition \| Level 1
Fair Value Measurements
Acquisition-related contingent consideration		0
Myoscience Acquisition \| Level 2
Fair Value Measurements
Acquisition-related contingent consideration		0
Myoscience Acquisition \| Level 3
Fair Value Measurements
Acquisition-related contingent consideration		35,797
Myoscience Acquisition \| Carrying Value
Fair Value Measurements
Acquisition-related contingent consideration		$ 35,797
Unsecured Debt \| Convertible Senior Notes Due 2022
Fair Value Measurements
Stated interest rate (as a percent)	2.375%	2.375%

FINANICIAL INSTRUMENTS (Details 2) - Myoscience Acquisition	9 Months Ended
	Sep. 30, 2019
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Projected years of payment for regulatory milestones	4 years 3 months
Contingent Consideration \| Minimum \| Fair Value, Inputs, Level 3 \| Measurement Input, Discount Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input, contingent consideration	0.0529
Contingent Consideration \| Minimum \| Fair Value, Inputs, Level 3 \| Measurement Input, Expected Milestone Payment
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input, contingent consideration	0.0000
Contingent Consideration \| Maximum \| Fair Value, Inputs, Level 3 \| Measurement Input, Discount Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input, contingent consideration	0.0564
Contingent Consideration \| Maximum \| Fair Value, Inputs, Level 3 \| Measurement Input, Expected Milestone Payment
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input, contingent consideration	1.0000

FINANCIAL INSTRUMENTS (Details 3) $ in Thousands	3 Months Ended	9 Months Ended
FINANCIAL INSTRUMENTS (Details 3) $ in Thousands	Sep. 30, 2019 USD ($)	Sep. 30, 2019 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total Milestone Payments Yet To Be Paid in Connection with MyoScience Acquisition	$ 80,000	$ 80,000
Contingent Consideration
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at December 31, 2018		0
New financial liabilities entered into on date of MyoScience Acquisition (April 9, 2019)		28,470
Fair value adjustments	7,300	7,327
Balance at September 30, 2019	$ 35,797	$ 35,797

FINANCIAL INSTRUMENTS (Details 4) - USD ($) $ in Thousands	3 Months Ended
FINANCIAL INSTRUMENTS (Details 4) - USD ($) $ in Thousands	Sep. 30, 2018	Sep. 30, 2019	Dec. 31, 2018
Fair Value Measurements
Unrealized Gain (Loss) on Investments	$ 5,400
Realized Investment Gains (Losses)	$ 900
Level 2
Fair Value Measurements
Cost		$ 250,635	$ 277,079
Gross Unrealized Gains		471	5
Gross Unrealized Losses		(24)	(285)
Fair Value		251,082	276,799
Short-term Investments \| Level 2
Fair Value Measurements
Cost		180,105	251,197
Gross Unrealized Gains		400	0
Gross Unrealized Losses		0	(269)
Fair Value		180,505	250,928
Long-Term Investments \| Level 2
Fair Value Measurements
Cost		70,530	25,882
Gross Unrealized Gains		71	5
Gross Unrealized Losses		(24)	(16)
Fair Value		70,577	25,871
Long-Term Investments \| Asset-backed securities \| Level 2
Fair Value Measurements
Cost		16,518	9,383
Gross Unrealized Gains		23	5
Gross Unrealized Losses		(7)	0
Fair Value		16,534	9,388
Long-Term Investments \| Corporate bonds \| Level 2
Fair Value Measurements
Cost		54,012	16,499
Gross Unrealized Gains		48	0
Gross Unrealized Losses		(17)	(16)
Fair Value		54,043	16,483
Short-term Investments \| Asset-backed securities \| Level 2
Fair Value Measurements
Cost		29,044	34,873
Gross Unrealized Gains		60	0
Gross Unrealized Losses		0	(33)
Fair Value		29,104	34,840
Short-term Investments \| Commercial paper \| Level 2
Fair Value Measurements
Cost		34,788	45,035
Gross Unrealized Gains		41	0
Gross Unrealized Losses		0	(30)
Fair Value		34,829	45,005
Short-term Investments \| Corporate bonds \| Level 2
Fair Value Measurements
Cost		116,273	171,289
Gross Unrealized Gains		299	0
Gross Unrealized Losses		0	(206)
Fair Value		$ 116,572	$ 171,083

STOCK PLANS (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
STOCK PLANS (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-Based Compensation
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	3,000,000		3,000,000
Document Period End Date			Sep. 30, 2019
Stock-based compensation expense	$ 9,244	$ 8,108	$ 24,461	$ 23,539
Compensation expense from stock options, employees	6,257	5,270	16,509	16,452
Compensation expense from stock options, non-employee awards	161	209	408	449
Restricted Stock or Unit Expense	2,639	2,479	6,950	6,088
Compensation expense from employee stock purchase plan	187	150	594	550
Stock-based compensation	9,244	8,108	$ 24,461	23,539
Purchase price of common stock, ESPP (as a percent)			85.00%
Shares issued under employee stock purchase plan (shares)			35,766
Cost of goods sold
Share-Based Compensation
Stock-based compensation expense	1,243	1,179	$ 3,490	3,431
Research and development
Share-Based Compensation
Stock-based compensation expense	1,297	1,122	3,772	2,770
Selling, general and administrative
Share-Based Compensation
Stock-based compensation expense	$ 6,704	$ 5,807	$ 17,199	$ 17,338

STOCK PLANS (Details 2)	9 Months Ended
STOCK PLANS (Details 2)	Sep. 30, 2019 $ / shares shares
Weighted Average Exercise Price
Weighted average fair value (in dollars per share)	$ 20.97
Employee Stock Option
Number of Options
Outstanding beginning of period (in shares) \| shares	5,722,818
Granted (in shares) \| shares	1,792,978
Exercised (in shares) \| shares	(251,169)
Forfeited (in shares) \| shares	(258,353)
Expired (in shares) \| shares	(125,316)
Outstanding end of period (in shares) \| shares	6,880,958
Weighted Average Exercise Price
Outstanding beginning of period (in dollars per share)	$ 41.69
Granted (in dollars per share)	42.81
Exercised (in dollars per share)	19.88
Forfeited (in dollars per share)	41.51
Expired (in dollars per share)	59.20
Outstanding at end of period (in dollars per share)	$ 42.46

STOCK PLANS (Details 3)	9 Months Ended
STOCK PLANS (Details 3)	Sep. 30, 2019 $ / shares shares
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Unvested at beginning of period (shares) \| shares	577,964
Granted (shares) \| shares	303,168
Vested (shares) \| shares	(190,586)
Forfeited (shares) \| shares	(49,611)
Unvested at end of period (shares) \| shares	640,935
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Unvested at beginning of period (usd per share) \| $ / shares	$ 42.14
Granted (usd per share) \| $ / shares	43.57
Vested (usd per share) \| $ / shares	45.56
Forfeited (usd per share) \| $ / shares	41.04
Unvested at end of period (usd per share) \| $ / shares	$ 41.88
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Risk free interest rate (as a percent)	2.02%
Expected volatility (as a percent)	53.88%
Expected term of options	5 years 2 months 19 days

STOCKHOLDERS' EQUITY (Details) - USD ($) $ in Thousands	9 Months Ended
STOCKHOLDERS' EQUITY (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Sep. 30, 2018
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance at beginning of period	$ (280)
Balance at end of period	447
Accumulated Net Unrealized Investment Gain (Loss)
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance at beginning of period	(280)	$ (454)
Other comprehensive loss before reclassifications	727	213
Balance at end of period	447	(241)
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent	$ 0	$ 0

NET INCOME (LOSS) PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Numerator for basic and diluted loss per share
Net loss	$ (6,087)	$ (640)	$ (6,128)	$ (8,756)
Denominator
Weighted average common shares outstanding (in shares)	41,645	40,995	41,423	40,833
Net loss per share:
Basic and diluted net income (loss) per common share (in USD per share)	$ (0.15)	$ (0.02)	$ (0.15)	$ (0.21)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

NET INCOME (LOSS) PER SHARE (Details 2) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
EARNINGS PER SHARE
Total	5,742	6,635	4,993	5,952
Employee Stock Option
EARNINGS PER SHARE
Total	5,443	5,988	4,816	5,392
Restricted Stock Units (RSUs)
EARNINGS PER SHARE
Total	266	618	154	528
Employee Stock
EARNINGS PER SHARE
Total	33	29	23	32

INCOME TAXES INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Domestic	$ (3,234)	$ 1,839	$ 2,345	$ (7,382)
Foreign	(2,582)	(2,541)	(9,552)	(1,366)
Income (loss) before income taxes	(5,816)	(702)	(7,207)	(8,748)
Income Tax Expense (Benefit)	271	(62)	(1,079)	$ 8
Income tax expense (less than)		$ 100	(100)
Valuation allowance on deferred tax assets	$ 1,800		$ 1,800

ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Jan. 01, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Business Acquisition [Line Items]
Non-recurring charge related to discontinuation		$ 100	$ 1,300	$ 100	$ 1,500
Myoscience Acquisition
Business Acquisition [Line Items]
Acquisition-related costs		7,600		12,100
Advisory Costs \| Myoscience Acquisition
Business Acquisition [Line Items]
Acquisition-related costs		200		4,100
Separation Costs, Asset Write-downs, and Other Restructuring Charges \| Myoscience Acquisition
Business Acquisition [Line Items]
Acquisition-related costs		100		700
Accounting Standards Update 2016-02
Business Acquisition [Line Items]
Business Exit Costs	$ (1,500)
Contingent Consideration
Business Acquisition [Line Items]
Fair value adjustments		$ 7,300		$ 7,327

ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - DepoCyte Product Discontinuance (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Jan. 01, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
DepoCyte Discontinuation [Line Items]
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation		$ 100	$ 1,300	$ 100	$ 1,500
DepoCyte Discontinuation [Roll Forward]
Acquisition-Related Separation Costs, Beginning Balance	$ 0			0
Acquisition-Related Separation Costs, Charges Incurred				480
Acquisition-Related Separation Costs, Cash Payments Made				(321)
Acquisition-Related Separation Costs, Ending Balance		159		159
Acquisition-Related Asset Write-Downs, Charges Incurred				193
Acquisition-Related Asset Write-Downs, Other, Including Non-Cash Activity				(193)
DepoCyt(e) Lease Costs, Beginning Balance	1,970			1,970
DepoCyt(e) Lease Costs, Ending Balance		0		0
Asset Retirement Obligations, Other Restructuring and Discontinuation Costs, Beginning Balance	282			282
Asset Retirement Obligations, Other Restructuring and Discontinuation Costs, Charges Incurred				167
Asset Retirement Obligations, Other Restructuring and Discontinuation Costs, Cash Payments Made				(307)
Asset Retirement Obligations, Other Restructuring and Discontinuation Costs, Ending Balance		597		597
Total, Beginning Balance	2,252			2,252
Total, Charges Incurred		(7,618)	$ (1,259)	(12,266)	$ (1,511)
Total, Cash Payments Made				(628)
Total, Ending Balance		$ 756		756
DepoCyte
DepoCyte Discontinuation [Roll Forward]
Total, Charges Incurred				$ 840
Accounting Standards Update 2016-02
DepoCyte Discontinuation [Roll Forward]
Total, Reclassifications	$ (1,500)

Subsequent Events (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Subsequent Events (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019	Sep. 30, 2019
Subsequent Event [Line Items]
Acquisition-related contingent consideration		$ 7,000	$ 7,000
Scenario, Forecast \| Achievement of Regulatory Milestone
Subsequent Event [Line Items]
Acquisition-related contingent consideration		5,000	5,000
Scenario, Forecast \| Achievement of Development and Commercial Milestones \| Subsequent Event
Subsequent Event [Line Items]
Acquisition-related contingent consideration	$ 10,000
Contingent Consideration [Member]
Subsequent Event [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings		$ 7,300	$ 7,327
Contingent Consideration [Member] \| Subsequent Event
Subsequent Event [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	$ 9,000